On this page
Quick Reference
Overview and Recommendations
Background
- •Define meningitis as the acute or chronic inflammation of the protective membranes surrounding the brain and spinal cord, specifically the leptomeninges. It is a critical global health challenge with significant geographic heterogeneity, such as the high burden seen in the African Meningitis Belt.
- •Identify the primary infectious etiologies, which vary by age and risk factors: and dominate adult bacterial cases, while is the leading cause in neonates. Viral or 'aseptic' meningitis is most frequently caused by and is generally less severe but more common.
- •Recognize the high morbidity associated with the condition, as more than 30% of survivors worldwide suffer from long-term neurological sequelae, including sensorineural hearing loss (SNHL), cognitive impairment, and seizure disorders.
- •Distinguish between acute (hours to days) and chronic (more than 4 weeks) forms. Tuberculous meningitis (TBM) and cryptococcal meningitis often present subacutely and are major causes of mortality in immunocompromised populations, particularly those with HIV/AIDS.
- •Consider non-infectious triggers such as drug-induced aseptic meningitis (DIAM)—often linked to NSAIDs or antibiotics—and systemic autoinflammatory diseases like (NPSLE) or GFAP astrocytopathy.
Evaluation
- •Suspect meningitis in any patient presenting with fever, severe headache, and nuchal rigidity (neck stiffness), though be aware that this 'classic triad' is present in less than half of confirmed cases. In neonates, look for non-specific signs like irritability, poor feeding, bulging fontanelles, or hypothermia (Temperature ≤ 36.0°C).
- •Perform a targeted physical exam for meningeal irritation using Kernig’s sign (resistance to knee extension with the hip flexed) and Brudzinski’s sign (involuntary hip flexion during passive neck flexion). Utilize the jolt accentuation of headache—increasing pain with rapid horizontal head rotation—as it is a highly sensitive sign for meningeal inflammation.
- •Assess for 'red flags' that indicate high-risk complications, such as rapidly progressive purpura (suggestive of meningococcemia), focal neurological deficits, papilledema, or a Glasgow Coma Scale (GCS) score < 12.
- •Order a non-contrast CT prior to performing a lumbar puncture (LP) only if specific contraindications are present: focal neurological deficits, new-onset seizures, papilledema, or known immunocompromise. Do not delay the first dose of antibiotics for imaging if an LP is deferred.
- •Obtain blood cultures and a simultaneous serum glucose level immediately upon arrival. Blood cultures are positive in 50-80% of patients with bacterial meningitis and may provide a diagnosis if the LP is 'dry' or contraindicated.
- •Perform a lumbar puncture to analyze cerebrospinal fluid (CSF) for opening pressure, cell count with differential, glucose, and protein. Typical bacterial findings include neutrophilic pleocytosis (>5 cells/μL), elevated protein, and a CSF/serum glucose ratio < 0.4.
- •Utilize rapid molecular diagnostics such as the Meningitis/Encephalitis panel, which can identify 14 common pathogens via multiplex PCR within approximately one hour, significantly improving time-to-targeted-therapy.
- •Evaluate for (TBM) in patients with subacute symptoms or high-risk backgrounds using CSF biomarkers (IFN-γ, IL-6) and molecular tools like CBNAAT or Loop-mediated isothermal amplification (LAMP), which has a sensitivity of ~62.5% in pediatric populations.
- •Screen for cryptococcal antigen (CrAg) in all HIV-positive patients with a CD4 count < 100 cells/μL, as high blood CrAg titers are strongly predictive of concurrent meningitis and increased mortality.
- •Rule out mimics such as (via CT or presence of xanthochromia in CSF) and autoimmune encephalitis (via MRI findings like linear perivascular radial enhancement in GFAP astrocytopathy).
Management
- •Administer empiric antimicrobial therapy within 60 minutes of patient arrival; every hour of delay is associated with increased mortality. For most adults, initiate Ceftriaxone 2 g IV every 12 hours and Vancomycin 15-20 mg/kg IV every 8-12 hours.
- •Add Ampicillin 2 g IV every 4 hours to the empiric regimen for patients over age 50, pregnant individuals, or those with immunocompromise to provide coverage for Listeria monocytogenes.
- •Administer adjunctive Dexamethasone 0.15 mg/kg IV every 6 hours (maximum 10 mg) starting 10-20 minutes before or concurrently with the first dose of antibiotics to reduce the risk of hearing loss and neurological sequelae in bacterial cases.
- •Continue dexamethasone for 4 days in patients confirmed to have Streptococcus pneumoniae meningitis; discontinue if the pathogen is found to be viral or a different bacterium where steroid benefit is less clear.
- •Manage (TBM) with a standard 4-drug regimen (Rifampin, Isoniazid, Pyrazinamide, and Ethambutol) plus adjunctive dexamethasone for 6-8 weeks. Consider high-dose Rifampin 35 mg/kg/day to improve CNS penetration, though its mortality benefit is still debated.
- •Treat HIV-associated cryptococcal meningitis using the AMBITION protocol: a single high dose of Liposomal Amphotericin B 10 mg/kg on Day 1, followed by 14 days of oral Flucytosine 100 mg/kg/day and Fluconazole 1200 mg/day.
- •Monitor and manage increased intracranial pressure (ICP) using head elevation to 30 degrees and osmotic therapy (Mannitol 0.5-1.0 g/kg). Consider external ventricular drainage (EVD) for patients with refractory hypertension or symptomatic hydrocephalus.
- •Implement seizure precautions and treat active seizures with benzodiazepines (e.g., Lorazepam 0.1 mg/kg IV), followed by maintenance anticonvulsants like Levetiracetam if cortical involvement is suspected.
- •Provide post-exposure prophylaxis (PEP) to close contacts of patients with N. meningitidis or H. influenzae type b using Ciprofloxacin 500 mg PO (single dose) or Rifampin 600 mg PO twice daily for 2 days.
- •Perform formal audiological diagnostic testing at the time of discharge or within 4 weeks of recovery to detect sensorineural hearing loss (SNHL), as early intervention is critical for preventing cognitive decline.
- •Avoid the use of adjunctive corticosteroids in HIV-positive adults with TBM, as trials have shown they may not provide the same survival benefit as seen in HIV-negative populations.
- •Refer to neurosurgery immediately if imaging reveals a (complicating ~1.9% of bacterial cases) or if there is evidence of obstructive hydrocephalus requiring a shunt.
Board Review — High Yield
- •Jolt accentuation — The most sensitive physical exam maneuver for identifying meningeal irritation (worsening headache with horizontal head rotation).
- •CSF/Serum Glucose Ratio < 0.4 — A classic laboratory finding strongly suggestive of bacterial, fungal, or tuberculous meningitis over viral causes.
- •Waterhouse-Friderichsen syndrome — Adrenal insufficiency caused by bilateral adrenal hemorrhage, a catastrophic complication of meningococcemia.
- •LTA4H genotype — A genetic marker that predicts whether a patient with tuberculous meningitis will benefit from adjunctive corticosteroids.
- •AMBITION-cm Trial — Validated a single high-dose of liposomal amphotericin B as part of an effective, less toxic induction regimen for cryptococcal meningitis.
- •Sensorineural hearing loss — The most common long-term sequela of bacterial meningitis, necessitating audiological follow-up for all survivors.
- •Dexamethasone timing — Must be given before or with the first dose of antibiotics to be effective in reducing inflammatory neurological damage.
- •Enterovirus — The most common cause of 'aseptic' meningitis, typically presenting with a benign, self-limiting course.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Meningitis is defined as inflammation of the leptomeninges and CSF, with etiology ranging from common bacteria to emerging zoonotic viruses like LCMV and Henipaviruses.
- ▸Tuberculous meningitis (TBM) uses a standardized 'Uniform Case Definition' categorizing cases as Definite, Probable, or Possible to guide management in high-burden areas.
- ▸Aseptic meningitis is most frequently caused by Enteroviruses, though emerging pathogens like Potosi and Lone Star viruses are increasingly identified via metagenomic sequencing.
Meningitis is defined as an inflammatory response affecting the leptomeninges (the arachnoid and pia mater) and the underlying (CSF) [21]D. This condition represents a critical challenge to global public health due to its diverse etiology, which spans bacterial, viral, fungal, and parasitic pathogens [21]D. The inflammation typically results from the invasion of the subarachnoid space by infectious agents, leading to a cascade of immunological responses that can impair mitochondrial function and metabolic regulation within the central nervous system (CNS) [21]D.
Synonyms and Alternate Nomenclature
Historically and clinically, meningitis is referred to by several terms depending on the context of the infection and the specific pathogen involved:
- Spinal Meningitis: A common lay term emphasizing the involvement of the membranes surrounding the spinal cord.
- Leptomeningitis: A precise anatomical term for inflammation of the leptomeninges [21]D.
- Invasive (IMD): A clinical syndrome caused by Neisseria meningitidis that encompasses both meningitis and meningococcemia (sepsis) [18]D[24]D.
- Neurolisteriosis: A specific designation for CNS infection caused by Listeria monocytogenes, which may present as meningitis, meningoencephalitis, or rhombencephalitis [17]D.
- Aseptic Meningitis: A clinical syndrome characterized by meningeal inflammation where routine bacterial cultures are negative, most frequently caused by viruses such as [26]D[29]D.
- Ventriculostomy-Related Infection (VRI): Also known as nosocomial meningitis or EVD-associated meningitis, occurring in patients with external ventricular drains [1][27]D.
Clinical Phases and Stages
The progression of meningitis is often categorized into distinct phases to guide diagnostic and therapeutic urgency. While these stages are most clearly defined in chronic forms like (TBM), they apply broadly to the clinical course of the disease:
- Prodromal Phase: The initial period characterized by non-specific symptoms such as fever, malaise, and headache [11]C[16]D. In TBM, this phase may last weeks, whereas in bacterial meningitis, it may be limited to a few hours.
- Progressive Phase: The stage where classic meningeal signs (e.g., neck stiffness, photophobia) and neurological deficits emerge [17]D[18]D. This phase marks the active migration of pathogens across the .
- Nadir (Peak Severity): The point of maximal clinical instability, often associated with the highest inflammatory burden, septic shock, or a 10-15% risk of mortality in bacterial cases [5]D[24]D.
- Plateau Phase: A period of clinical stabilization following the initiation of appropriate antimicrobial therapy, such as rifampicin-based regimens for susceptible strains [2][10]C.
- Recovery Phase: The resolution of inflammation and gradual improvement in neurological function, though patients may suffer permanent sequelae [18]D.
Classification by Etiology and Duration
Meningitis is classified primarily by the causative agent and the temporal onset of symptoms. Acute meningitis typically develops over hours to days, while chronic meningitis persists for more than 4 weeks.
Bacterial Meningitis (Suppurative)
Bacterial meningitis is characterized by a purulent inflammatory response. Common pathogens include Neisseria meningitidis (notably serogroups B, W, and Y), Streptococcus pneumoniae, and type b [10]C[14]C[25]D[30]D. Rare cases may involve probiotic-related organisms like Clostridium butyricum in neonates [13]C.
Viral and Aseptic Meningitis
Viral meningitis is the most frequent form, often caused by non-polio enteroviruses (NPEVs) such as Echovirus 6, 18, and 30, or Coxsackievirus B1 [11]C[26]D[29]D. Emerging zoonotic viruses also contribute to this category, including Lymphocytic Choriomeningitis Virus (LCMV), Henipaviruses (Nipah), and Bunyaviruses (Potosi and Lone Star viruses) [4]D[9]C[15]C.
Tuberculous Meningitis (TBM)
TBM is the most severe manifestation of tuberculosis [3][16]D. It is classified using a uniform case definition to standardize research and clinical care:
- Definite TBM: Clinical symptoms plus microbiological confirmation (e.g., M. tuberculosis identified in CSF via culture or molecular tools) [3][16]D.
- Probable TBM: Clinical symptoms plus a high diagnostic score based on CSF parameters, imaging, and evidence of extraneural TB [3][16]D.
- Possible TBM: Clinical suspicion where the diagnostic score is lower but no alternative diagnosis is more likely [3][16]D.
Parasitic and Eosinophilic Meningitis
This variant is defined by the presence of eosinophils in the CSF, most commonly caused by the rat lungworm Angiostrongylus cantonensis [12]C[23]D. Infection typically occurs through the ingestion of intermediate hosts like Pomacea snails [23]D.
| Variant | Key Distinguishing Feature | Associated Pathogens/Factors |
|---|---|---|
| Bacterial | Suppurative inflammation; high fatality (10-15%) | N. meningitidis, S. pneumoniae, H. influenzae [18]D[24]D[25]D |
| Viral (Aseptic) | Most common; often seasonal; CSF pleocytosis | Enteroviruses (E-18, E-30), LCMV, Bunyaviruses [9]C[15]C[29]D |
| Tuberculous | Subacute course; high neurological disability | Mycobacterium tuberculosis [3][16]D |
| Parasitic | Eosinophilic pleocytosis in CSF | Angiostrongylus cantonensis [12]C[23]D |
| Nosocomial | Associated with External Ventricular Drains (EVD) | Staphylococci, Gram-negative bacilli [1][27]D |
| Neonatal | Early-onset (within 7 days) vs. late-onset | Group B Streptococcus, E. coli, C. butyricum [13]C[28]D |
Epidemiology and Risk Factors
- ▸Neurological sequelae, including sensorineural hearing loss and cognitive decline, affect over 30% of meningitis survivors globally [33, 34].
- ▸Anatomical breaches, such as CSF leaks or cochlear implants, account for approximately 4.3% of pediatric bacterial meningitis cases [51].
- ▸The African Meningitis Belt and specific seasonal windows (e.g., summer for SSHV and TOSV) represent periods of peak epidemiological risk [47, 48, 58].
The of is characterized by significant geographic heterogeneity, age-specific vulnerability, and a shifting landscape of etiologic agents driven by vaccination programs and emerging pathogens. While global efforts have reduced the burden of classic bacterial pathogens, the disease remains a major cause of morbidity and mortality, with neurological sequelae affecting more than 30% of survivors worldwide [33].
Global Incidence and Prevalence
Incidence rates vary drastically by region and pathogen. In the United States, the annual incidence of Group A Streptococcus (GAS) meningitis is relatively low, ranging from 0.02 to 0.07 per 100,000 persons [53]D. However, in resource-limited settings, the burden is substantially higher. For instance, a meta-analysis of laboratory-confirmed bacterial meningitis in South Africa reported an overall pooled prevalence of 38.01% (95% CI: 0.26–0.50) among suspected cases [36]. In Ghana, which lies within the African Meningitis Belt, the disease remains a critical public health concern with high fatality rates, particularly in northern regions [37].
Specific complications also show measurable prevalence; brain abscesses complicate approximately 1.9% (95% CI: 1.5–2.5) of bacterial meningitis episodes, with a higher prevalence of 3.8% observed in cases caused by Streptococcus pneumoniae [41]. In the context of , case fatality rates remain greater than 25% in HIV-associated cohorts, often exacerbated by co-infections such as Epstein-Barr virus (EBV) or Cytomegalovirus (CMV) [38].
Demographic Distribution
Age is a primary determinant of meningitis risk and etiology.
- Neonates and Infants: Infants under 1 year of age face the highest risk for several forms of the disease. The incidence of GAS meningitis in this group is 0.23 per 100,000, significantly higher than in older populations [53]D. Neonatal suppurative meningitis remains a high-morbidity condition, with pathogens evolving and showing increasing drug resistance [45].
- Children and Adolescents: In South Africa, the highest prevalence of bacterial meningitis (7.67%) was identified in the 6–17 year age group [36].
- Elderly: There is an increasing incidence of cryptococcal meningitis among non-HIV elderly populations (aged ≥60 years), who may present with distinct clinical features and higher mortality risks compared to younger non-HIV patients [42].
Geographic and Seasonal Variations
Geographic location dictates exposure to specific environmental and vector-borne pathogens. The "African Meningitis Belt" continues to experience high climate-health vulnerability. In Central Ethiopia, bacterial meningitis shows a significant association with climatic variables, often peaking during specific environmental conditions [58]D.
Arboviral meningitis exhibits clear seasonality and geographic clustering:
- Toscana Virus (TOSV): An emerging sandfly-borne virus causing aseptic meningitis in Mediterranean and Middle Eastern regions. Cases in non-endemic areas like Austria are typically imported, with clusters identified between July and September following travel to endemic zones like Italy [48]C.
- Snowshoe Hare Virus (SSHV): This arbovirus circulates in northern latitudes (e.g., Canada and the US). Clusters of pediatric meningoencephalitis have been reported during the summer months, suggesting underrecognized local transmission [47]C.
- Echovirus 18: Recently detected in West Africa (Niger), this pathogen is an important cause of aseptic meningitis in young children, sometimes associated with severe outcomes in patients with comorbidities like sickle cell anemia [49]C.
Risk Factors and Predisposing Conditions
Risk factors for meningitis can be categorized into anatomical, immunological, and environmental exposures. Anatomical defects that breach the protective meningeal barrier are high-risk triggers. In a nationwide French cohort, 4.3% of pediatric bacterial meningitis cases occurred in children with known cerebrospinal fluid (CSF) leakage or cochlear implants [51]D. While prophylactic are sometimes used for closed basilar skull fractures, their effectiveness in preventing subsequent meningitis remains a subject of clinical debate [43].
Immunocompromised states, particularly HIV/AIDS, are the strongest risk factors for fungal and (TBM). In Thailand, TBM remains a severe manifestation of tuberculosis, with outcomes heavily influenced by the timing of treatment initiation [3]. In HIV-negative patients, TBM can still occur and may be complicated by paradoxical reactions—an immune-mediated worsening of symptoms after starting anti-tubercular therapy [40].
Environmental and occupational exposures also play a role. Mass gatherings, such as the Hajj and Umrah pilgrimages, enhance the transmission of Neisseria meningitidis due to close quarters, necessitating strict vaccination policies [46]. Occupational exposure to rodent excreta increases the risk of Lymphocytic Choriomeningitis Virus (LCMV), with a seroprevalence of 1.4% found among forestry workers in certain regions of Germany [55]D.
| Risk Factor | Association / Prevalence | Evidence Level |
|---|---|---|
| HIV Infection | Major risk for Cryptococcal and TBM; >25% mortality in CM [38][39] | 1b |
| CSF Leak / Cochlear Implant | Found in 4.3% of pediatric bacterial meningitis cases [51]D | 5 |
| Age < 1 Year | Highest GAS meningitis incidence (0.23 per 100,000) [53]D | 5 |
| Basilar Skull Fracture | Potential for post-traumatic meningitis; prophylaxis debated [43] | 2b |
| Forestry Work | 1.4% seroprevalence for LCMV (rodent-borne) [55]D | 5 |
| Hajj/Umrah Pilgrimage | Increased carriage and transmission of N. meningitidis [46] | 2a |
| Sickle Cell Anemia | Associated with severe Echovirus 18 aseptic meningitis [49]C | 4 |
| Elderly (≥60 years) | Increasing risk group for non-HIV Cryptococcal meningitis [42] | 2b |
Etiology and Triggering Factors
- ▸Streptococcus pneumoniae remains the most common bacterial cause globally, with its pathogenesis driven by TLR and NLRP3-mediated cytokine storms.
- ▸Drug-induced aseptic meningitis (DIAM) is most frequently triggered by NSAIDs and antibiotics, often mimicking infectious presentations.
- ▸Anatomical defects, such as CSF leaks or cochlear implants, are present in over 4% of pediatric bacterial meningitis cases.
Meningitis is defined as the acute or chronic inflammation of the protective membranes (meninges) surrounding the brain and spinal cord [72]D. The etiology of meningitis is remarkably diverse, spanning infectious pathogens—including bacteria, viruses, fungi, and parasites—as well as non-infectious triggers such as medications, systemic autoinflammatory diseases, and anatomical defects [61][71]C[72]D. The primary mechanism of pathogenesis involves the invasion of the central nervous system (CNS) by pathogens that cross the (BBB), triggering a dysregulated immune response characterized by cytokine storms and neutrophil infiltration [65]D.
Bacterial Etiology and Pathogenesis
Bacterial meningitis remains a critical global health threat due to high mortality and the prevalence of neurological sequelae, such as sensorineural hearing loss [33][34]. The most common pathogens in community-acquired cases are Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), type B, and Group B Streptococcus (S. agalactiae) [72]D[78]D.
The molecular mechanism of bacterial invasion involves the disruption of the BBB. Pathogens are recognized by microglial receptors, specifically Toll-like receptors (TLRs) and the NLRP3 inflammasome [65]D. This recognition triggers the release of pro-inflammatory cytokines, including IL-1β and TNF-α, which increase BBB permeability and facilitate massive neutrophil infiltration [65]D. In S. pneumoniae infections, the release of bacterial toxins during lysis can exacerbate this inflammatory damage, leading to cerebral edema and neuronal injury [79]D.
Specific bacterial triggers include:
- Streptococcus pneumoniae: The most frequent cause of and children [72]D[78]D. It is associated with high rates of antimicrobial resistance (AMR) to penicillins and cephalosporins in certain regions [35].
- Mycobacterium tuberculosis: Causes (TBM), a lethal form of the disease where the host immune response itself drives significant brain injury [59][73]D.
- Escherichia coli O45: An emerging multidrug-resistant serotype particularly relevant in neonatal meningitis [77]D.
- Corynebacterium striatum: A rare cause typically associated with indwelling devices, such as lumbar-peritoneal (LP) shunts, especially in patients with comorbidities like diabetes [67]C.
Viral and Aseptic Etiology
Viral meningitis, often termed "aseptic meningitis," is generally more common and less severe than bacterial forms, though certain viruses like Varicella-zoster virus (VZV) can cause significant disability [81]D.
- Enteroviruses: These are the most frequently detected pathogens in aseptic meningitis surveillance, with various genotypes circulating seasonally [82]D.
- Varicella-zoster virus (VZV): VZV meningitis outcomes are closely linked to viral load and the patient's level of consciousness at presentation [81]D.
- Toscana virus (TOSV): An emerging sandfly-borne virus prevalent in Mediterranean regions, often imported to other areas by travelers [48]C.
- Lymphocytic choriomeningitis virus (LCMV): A rodent-borne pathogen that can cause severe congenital infections and meningitis in urban populations [75]D.
Fungal and Opportunistic Triggers
Cryptococcus neoformans is the leading cause of non-viral meningitis in the United States [64]D. While historically associated with HIV/AIDS, the has shifted due to effective antiretroviral therapy (ART). Current high-risk groups include solid-organ transplant recipients and apparently healthy individuals [64]D[70]C. In these patients, post-infectious inflammatory syndromes can complicate the clinical course even after the fungus is cleared [64]D.
Non-Infectious and Drug-Induced Causes
Drug-induced aseptic meningitis (DIAM) is a rare but important adverse reaction. It typically presents with a mean patient age of 47 years and a slight female predominance (55%) [61].
- Common Implicated Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), (e.g., trimethoprim-sulfamethoxazole), and monoclonal antibodies [61].
- Systemic Diseases: Adult-onset Still's disease (AOSD) can rarely present with aseptic meningitis, characterized by high spiking fevers, evanescent rash, and polyarthritis [71]C.
Anatomical and Host Risk Factors
Certain host conditions significantly increase the risk of developing meningitis by providing a direct pathway for pathogens or impairing the immune response:
- CSF Leakage and Cochlear Implants: These anatomical breaches account for approximately 4.3% of bacterial meningitis cases in children [51]D.
- Primary Immunodeficiencies: Conditions like X-linked agammaglobulinemia (XLA), characterized by absent antibody production, predispose individuals to recurrent purulent meningitis [68]C.
- Metabolic Markers: A high blood urea nitrogen to serum albumin (BUN/ALB) ratio upon admission has been identified as a prognostic marker for unfavorable outcomes in bacterial meningitis, reflecting the severity of the systemic inflammatory state [62].
| Cause | Category | Frequency/Context | Associated Subtype | Key Reference |
|---|---|---|---|---|
| Streptococcus pneumoniae | Bacterial | Most common (Adults/Children) | Serotypes covered by PCV-13/10 | [72]D[78]D |
| Neisseria meningitidis | Bacterial | Common (Community-acquired) | Serogroups A, B, C, W, Y | [72]D |
| Enteroviruses | Viral | Most common (Aseptic) | Various genotypes | [82]D |
| Cryptococcus neoformans | Fungal | Leading non-viral (US) | HIV and Non-HIV (Transplant) | [64]D |
| Mycobacterium tuberculosis | Bacterial | High mortality | Tuberculous meningitis (TBM) | [59][73]D |
| NSAIDs | Drug-Induced | Rare adverse reaction | DIAM | [61] |
| Toscana virus | Viral | Emerging (Sandfly-borne) | Imported via travel | [48]C |
| Escherichia coli O45 | Bacterial | Emerging (Neonatal) | Multidrug-resistant | [77]D |
| VZV | Viral | Variable severity | Linked to high viral load | [81]D |
| AOSD | Autoimmune | Very Rare | Systemic autoinflammatory | [71]C |
Pathophysiology
- ▸Meningitis pathophysiology is driven by a 'cytokine storm' (TNF-α, IL-1β, IL-6) triggered by TLR and NLRP3 activation in the subarachnoid space.
- ▸The LTA4H genotype is a critical immunogenetic determinant of the inflammatory phenotype and corticosteroid response in tuberculous meningitis.
- ▸BBB disruption in autoimmune meningitis (NPSLE) is mediated by the Type I Interferon axis and endothelial dysfunction, allowing autoantibody penetration.
The pathophysiology of meningitis involves a complex interplay between pathogen virulence factors and the host's dysregulated immune response. While the initial trigger may be infectious (bacterial, viral, fungal) or non-infectious (autoimmune, drug-induced), the final common pathway involves the disruption of the (BBB), the recruitment of inflammatory cells into the subarachnoid space, and the subsequent development of cerebral edema and neuronal injury [65]D[72]D.
Mechanisms of Pathogen Entry and BBB Disruption
Pathogens typically reach the central nervous system (CNS) through three primary routes: hematogenous spread, direct contiguous spread, or retrograde axonal transport. In hematogenous spread, pathogens must survive systemic circulation and adhere to the cerebral vascular endothelium [65]D. Direct extension occurs in the setting of anatomical defects, such as cerebrospinal fluid (CSF) leakage (found in 4.3% of pediatric bacterial meningitis cases) or cochlear implants [51]D. Retrograde transport is characteristic of specific viruses, such as the B virus (herpes B), which travels along nerves following a macaque bite [89]C.
Step-by-Step Mechanism of Bacterial Invasion:
- Colonization and Mucosal Invasion: Pathogens like Neisseria meningitidis or Streptococcus pneumoniae colonize the nasopharynx and cross the mucosal barrier into the bloodstream [72]D[86]C.
- Survival in Circulation: Pathogens evade host complement and phagocytosis to maintain high-grade bacteremia.
- BBB Crossing: Bacteria utilize virulence factors to disrupt tight junction proteins (e.g., occludin, claudin-5) and activate endothelial cells [65]D.
- Subarachnoid Space Entry: Once in the CSF, which has limited initial immune surveillance, pathogens multiply rapidly, triggering a massive inflammatory influx [65]D.
The Inflammatory Cascade and Cytokine Storm
The presence of pathogens or autoantigens in the CSF triggers the innate immune system. Microglia and astrocytes recognize pathogen-associated molecular patterns (PAMPs) via Toll-like receptors (TLRs) and the NLRP3 inflammasome [65]D. This activation leads to the release of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6 [65]D[88].
In (TBM), the host response is heavily influenced by the Leukotriene A4 hydrolase (LTA4H) genotype. Patients with the TT genotype exhibit a hyperinflammatory phenotype, while those with the CC genotype show lower levels of inflammation [84]. This genetic variation explains why adjunctive dexamethasone (e.g., 0.4 mg/kg/day) provides a survival benefit in some patients but not others [84]. Furthermore, elevated levels of IFN-γ and IL-6 in the CSF have been positively correlated with severe neurocognitive impairment in TBM survivors [88].
Autoimmune and Neuropsychiatric Pathogenesis
In conditions like Neuropsychiatric Systemic Lupus Erythematosus (NPSLE), the pathophysiology shifts toward a loss of self-tolerance and B-cell dysregulation [90]C. The central axis involves the overproduction of Type I Interferons (IFN-I), which promotes BBB breakdown and allows the entry of vascular autoantibodies and immune cells into the brain parenchyma [95]D[103]D.
Molecular Pathway of NPSLE Meningeal Involvement:
- Step 1: Systemic inflammation leads to endothelial activation and increased BBB permeability [97]D.
- Step 2: Entry of autoantibodies (e.g., anti-dsDNA, anti-ribosomal P) into the CNS [90]C.
- Step 3: Activation of microglia by self-nucleic acids and IFN-I [95]D.
- Step 4: Immune-metabolic remodeling, including a serotonin-kynurenine imbalance, which contributes to cortical vulnerability and neuropsychiatric symptoms [100]D.
Consequences of Meningeal Inflammation
The intense inflammatory response results in several physiological derangements:
- Vasogenic Edema: Increased BBB permeability allows fluid and plasma proteins to enter the extracellular space [65]D.
- Cytotoxic Edema: Toxic mediators (reactive oxygen species, nitric oxide) released by neutrophils and microglia cause cellular swelling and neuronal death [65]D.
- Interstitial Edema: Obstruction of CSF outflow at the arachnoid granulations leads to hydrocephalus and increased intracranial pressure (ICP) [86]C.
- Vasculitis: Inflammation of the subarachnoid blood vessels can lead to cerebral infarction or hemorrhage [92]C.
In fungal infections like Cryptococcal meningoencephalitis, a unique phenomenon known as Post-Infectious Inflammatory Response Syndrome (PIIRS) can occur. This is characterized by clinical deterioration despite effective antifungal therapy, driven by an exuberant T-cell mediated immune response to fungal antigens [64]D[94]C.
| Mediator | Target/Source | Pathophysiological Role |
|---|---|---|
| TNF-α / IL-1β | Microglia/Neutrophils | Primary drivers of BBB disruption and fever [65]D |
| IFN-γ | Th1 Cells | Correlates with neurocognitive sequelae in TBM [88] |
| Anti-dsDNA | Neuronal Antigens | Mediates tissue damage in NPSLE [90]C |
| Anti-ribosomal P | CNS Neurons | Associated with diffuse neuropsychiatric manifestations [90]C |
| Type I Interferon | Innate Immune Cells | Central axis for neuroinflammation in lupus [95]D |
| Etiology | Primary Mechanism | Key Feature |
|---|---|---|
| Bacterial | Neutrophil-driven inflammation | Rapid BBB breakdown and high ICP [65]D[72]D |
| Tuberculous | Granulomatous inflammation | LTA4H genotype-dependent severity [84] |
| Cryptococcal | PIIRS (Immune Reconstitution) | T-cell mediated response to fungal debris [64]D |
| Autoimmune | B-cell dysregulation | Autoantibody-mediated neuronal injury [90]C[95]D |
| Drug-Induced | Hypersensitivity (Type III/IV) | Aseptic pleocytosis following NSAID or IVIG use [61] |
History and Physical Examination
- ▸The classic triad of fever, headache, and nuchal rigidity is often absent in neonates, where hypothermia (≤ 36.0°C) may be the primary sign of invasive infection.
- ▸Bacteria hijack meningeal nociceptors to promote CNS invasion and generate the characteristic severe headache of meningitis.
- ▸Post-surgical meningitis, including rare fungal etiologies like Candida, should be suspected in patients with recent transsphenoidal or sinus procedures, especially if a CSF leak is present.
The clinical presentation of meningitis varies significantly by age, etiology, and host immune status. While the classic triad of fever, headache, and nuchal rigidity is well-recognized, its absence does not exclude the diagnosis, particularly in neonates and immunocompromised individuals [109][116]D.
Presenting Symptoms
In adults, the onset of bacterial meningitis is typically acute, with symptoms progressing over hours to days. (TBM) often follows a more subacute timeline, with symptoms evolving over days to weeks [115]D[122]D.
- Headache and Pain: Headache is a hallmark feature, often described as severe and generalized. Recent evidence suggests that bacteria hijack meningeal nociceptors to promote central nervous system (CNS) invasion and exacerbate pain signaling [127]D.
- Fever: Fever ≥ 38.0°C is common in bacterial meningitis [60][118]D. However, hypothermia (Temperature ≤ 36.0°C) is a critical red flag in neonates (0-60 days), as it may be the only sign of an invasive bacterial infection (IBI) [116]D.
- Pediatric Presentation: Febrile infants aged ≤ 28 days are at the highest risk for bacterial meningitis, with an incidence of 36 per 100,000 live births in some cohorts [114]D. Symptoms in this age group are often non-specific, including irritability, poor feeding, and bulging fontanelles [109][113]D.
- Prodromal Features: A history of recent upper respiratory infection, otitis media, or sinusitis may precede community-acquired cases [120]D. In hypervirulent Klebsiella pneumoniae (hvKP) cases, a primary urinary tract infection may serve as the portal for hematogenous dissemination [111]C.
Neurological Examination Findings
A systematic neurological examination is essential for identifying meningeal irritation and potential complications.
Meningeal Signs
Meningeal irritation results in protective muscle spasms when the meninges are stretched. The following maneuvers are standard:
- Nuchal Rigidity: Passive flexion of the neck is limited by painful muscle spasms.
- Kernig’s Sign: With the patient supine and the hip flexed at 90°, resistance or pain upon passive extension of the knee suggests meningeal irritation.
- Brudzinski’s Sign: Passive flexion of the neck results in spontaneous flexion of the hips and knees.
- Jolt Accentuation of Headache: The patient is asked to rotate their horizontally at a frequency of 2-3 times per second; an increase in headache intensity is a highly sensitive sign for meningitis.
Systemic Neurological Assessment
- Cranial Nerves: Sensorineural hearing loss (SNHL) is a frequent sequela, particularly in H. influenzae or S. pneumoniae infections [34][126]D. Bilateral deafness can occur rapidly in hvKP meningitis [111]C.
- Mental Status: Altered level of consciousness (LOC) or persistent altered mental status despite therapy should prompt investigation for meningoencephalitis or vasculitis [69]C[81]D[112]C.
- Motor and Movement: While rare, movement disorders such as chorea may be seen in neuropsychiatric systemic lupus erythematosus (NPSLE), which can mimic or complicate meningitis [108][119]D.
Phenotypic Variants
Different etiologies present with distinct clinical clusters, as summarized in the table below.
| Variant | Key Features | Frequency/Context |
|---|---|---|
| Bacterial Meningitis (BM) | Acute onset, high fever, severe triad, rapid progression [115]D. | Most common acute form. |
| Tuberculous Meningitis (TBM) | Subacute onset, cranial nerve palsies, weight loss, HIV association [122]D. | Common in endemic areas [115]D. |
| Viral (VZV) Meningitis | Generally benign but can cause severe disability or altered LOC [81]D. | Often associated with a rash. |
| Post-Surgical Meningitis | Occurs after transsphenoidal or sinus surgery; may involve Candida [110]C[120]D. | Risk increased by CSF leaks [117]D. |
| Eosinophilic Meningitis | Headache, peripheral eosinophilia, and cerebral vasculitis [112]C. | Rare; infectious or non-infectious. |
Red Flags
Certain findings necessitate immediate intervention or admission to the Pediatric Intensive Care Unit (PICU):
- Respiratory Compromise: Rapidly declining GCS or status epilepticus requiring mechanical ventilation [69]C[109].
- Autonomic Instability: Hypotension or severe hypothermia in neonates [116]D.
- Rapid Neurological Decline: Development of focal deficits or rapidly progressive hearing loss [111]C.
- CSF Leakage: History of spontaneous lateral skull base leaks or temporal bone fractures increases the risk of recurrent meningitis [107][124]D.
Atypical Presentations
Clinicians must maintain a high index of suspicion in the following scenarios:
- Hypothermic Infants: Infants aged 0-60 days with a temperature ≤ 36.0°C have a 0.29% prevalence of IBI [116]D.
- Incomplete Evaluation: Infants pre-treated with may have negative cultures but persistent clinical signs [113]D.
- Sinus Surgery Complications: Meningitis may occur as a rare (0.24%) complication of endoscopic sinus surgery, often secondary to an unrecognized CSF leak [120]D.
- Climate-Sensitive Trends: In certain regions, bacterial meningitis incidence correlates with specific climatic variables, such as temperature and rainfall patterns [58]D.
| Feature | Bacterial Meningitis | Tuberculous Meningitis | Viral (VZV) Meningitis |
|---|---|---|---|
| Onset | Acute (hours-days) | Subacute (days-weeks) | Acute |
| Triad Severity | High | Moderate | Mild-Moderate |
| Cranial Nerve Palsy | Less common | Common (e.g., CN VI) | Rare |
| Associated Signs | Purpura (if N. meningitidis) | Weight loss, night sweats | Vesicular rash |
| Outcome Risk | High mortality/SNHL [34] | High neurological sequelae [122]D | Generally benign [81]D |
Diagnosis and Workup
- ▸Lumbar puncture and CSF analysis remain the diagnostic gold standard, but molecular methods like multiplex PCR and mNGS are essential for culture-negative or complex cases.
- ▸Timing is critical: audiological testing should be performed early post-infection to mitigate the long-term impact of meningitis-associated hearing loss.
- ▸In resource-limited settings, LAMP testing provides superior sensitivity over CBNAAT for the rapid diagnosis of tuberculous meningitis in children.
The diagnosis of meningitis requires a high index of clinical suspicion followed by rapid, systematic laboratory and imaging confirmation. Because bacterial meningitis carries significant mortality and morbidity, including sensorineural hearing loss (SNHL) [34], diagnostic procedures must not delay the initiation of empiric therapy if a lumbar puncture (LP) is contraindicated or deferred. The diagnostic process integrates clinical presentation, cerebrospinal fluid (CSF) analysis, and increasingly, advanced molecular techniques like multiplex PCR and metagenomic next-generation sequencing (mNGS) [66][104]D.
Diagnostic Criteria
Formal diagnosis is typically based on a combination of clinical signs and laboratory evidence of meningeal inflammation.
- Required Features: Clinical evidence of meningeal irritation (fever, headache, nuchal rigidity, or altered mental status) plus CSF pleocytosis (typically >5 cells/μL).
- Supportive Features: Positive Gram stain, culture, or PCR from CSF; positive blood cultures in the setting of clinical meningitis; or characteristic neuroimaging findings such as leptomeningeal enhancement [86]C[91]C.
- Exclusion Criteria: Alternative diagnoses explaining the clinical picture, such as primary intracranial hemorrhage or non-inflammatory encephalopathies, though these may coexist in complex cases like neuropsychiatric systemic lupus erythematosus (NPSLE) [32].
Laboratory Tests
Laboratory evaluation begins with simultaneous blood and CSF sampling.
- Cerebrospinal Fluid (CSF) Analysis: This is the gold standard. Essential parameters include cell count with differential, glucose (and a simultaneous serum glucose to calculate the CSF/serum ratio <0.4), and protein levels. In bacterial meningitis, typical findings include neutrophilic pleocytosis, elevated protein, and low glucose. However, in neonatal cases, CSF cultures may remain negative despite clinical disease, necessitating the use of multiplex PCR [86]C.
- Molecular Diagnostics: The BioFire FilmArray Meningitis/Encephalitis (ME) panel is a multiplex PCR that significantly improves diagnostic yield and speed, particularly in pediatric populations [66]. For cases where standard tests are negative, mNGS (e.g., using the UG 100 platform) offers near-universal pathogen detection with high sensitivity (93% agreement with orthogonal tests) [104]D.
- (TBM) Specifics: Diagnosis of TBM is challenging. The Loop-mediated isothermal amplification (LAMP) test has shown higher sensitivity (62.5%) compared to CBNAAT (41.67%) in pediatric populations, making it a valuable tool in resource-limited settings [135]D. CSF biomarkers such as IFN-γ, IL-6, and TNF-α are also elevated in TBM and correlate with neurocognitive outcomes [88].
- Serum Biomarkers: The blood urea nitrogen to serum albumin (BUN/ALB) ratio is an emerging prognostic marker; higher ratios are associated with unfavorable 3-month outcomes in bacterial meningitis [62].
Imaging
Neuroimaging is primarily used to rule out contraindications to LP (e.g., mass effect) and to identify complications.
- Magnetic Resonance Imaging (MRI): MRI with contrast is the modality of choice for detecting leptomeningeal enhancement, ventriculitis, or infarcts [86]C[91]C. In specific conditions like GFAP astrocytopathy, MRI may show characteristic linear perivascular radial gadolinium enhancement [131]. In NPSLE, MRI may reveal a "leukodystrophy-like" phenotype with diffuse white matter lesions [85].
- Advanced Imaging: Experimental PET imaging using radiolabeled dendrimers is being explored to visualize microglia-mediated neuroinflammation in TBM [73]D. Artificial intelligence (AI) models are also being developed to improve the diagnostic performance of neuroimaging in complex inflammatory mimics like NPSLE [130].
Electrodiagnostic Studies
While not routine for all meningitis cases, electrodiagnostic studies (NCS/EMG) are critical when the differential includes Guillain-Barré syndrome (GBS), which can rarely manifest as a complication of NPSLE [90]C. Findings typically include:
- Cytoalbuminologic Dissociation: High CSF protein with a normal cell count [90]C.
- Conduction Abnormalities: Reduced motor nerve conduction velocities and prolonged F-wave latencies, indicating demyelination or axonal loss [90]C.
Diagnostic Algorithm
- Step 1: Clinical Assessment: Identify the "classic triad" (fever, neck stiffness, altered mental status). Assess for risk factors like CSF leakage or cochlear implants [51]D.
- Step 2: Safety Check: Perform a funduscopic exam and neurological assessment. Order a CT prior to LP if there are focal deficits, papilledema, or new-onset seizures to rule out herniation risk.
- Step 3: Primary Labs: Obtain blood cultures and start empiric if LP is delayed. Perform LP for CSF opening pressure, chemistry, and microbiology.
- Step 4: Molecular/Specialized Testing: If Gram stain is negative, utilize multiplex PCR [66]. For suspected TBM, use LAMP or CBNAAT [135]D. For suspected zoonotic causes (e.g., B virus after a monkey bite or ), order specific PCR and serology [89]C[98]D.
- Step 5: Follow-up: Perform formal audiological testing post-discharge to detect sensorineural hearing loss [34].
| Test | Finding | Timing | Sensitivity | Specificity |
|---|---|---|---|---|
| CSF Culture | Bacterial growth | 24–72 hours | 70–85% | ~100% |
| Multiplex PCR (BioFire) | Pathogen DNA/RNA | <2 hours | High [66] | High [66] |
| mNGS (Ultima UG 100) | Universal pathogen detection | 24–48 hours | 93% [104]D | 63% [104]D |
| LAMP (for TBM) | M. tuberculosis DNA | <2 hours | 62.5% [135]D | 84.6% [135]D |
| CBNAAT (for TBM) | M. tuberculosis DNA | <4 hours | 41.7% [135]D | 100% [135]D |
| MAT (Leptospirosis) | Agglutination titers | 10–14 days | Varies [98]D | High [98]D |
Differential Diagnosis of Meningitis
- ▸Antibiotic administration prior to lumbar puncture occurs in nearly 45% of cases and significantly impairs the sensitivity of CSF cultures, necessitating the use of molecular methods like multiplex PCR or mNGS.
- ▸GFAP astrocytopathy is a critical autoimmune mimic of infectious meningitis, often distinguishable by linear perivascular radial enhancement on MRI and a positive response to corticosteroids.
- ▸The presence of altered mental status, focal neurological deficits, or seizures should shift the differential toward encephalitis or brain abscess rather than isolated meningitis.
The differential diagnosis of meningitis is broad, encompassing infectious, autoimmune, and neoplastic etiologies that often present with overlapping clinical features such as fever, headache, and meningismus. Distinguishing between these entities is critical, as strategies vary significantly—ranging from urgent antimicrobial therapy for bacterial pathogens to immunosuppression for autoimmune mimics like (GFAP) astrocytopathy [131][143]C.
Diagnostic Criteria
Formal diagnosis of meningitis requires a combination of clinical suspicion and laboratory confirmation. While the classic triad of fever, neck stiffness, and altered mental status is well-known, it is often incomplete.
- Required Features: Evidence of meningeal inflammation, typically defined as a cerebrospinal fluid (CSF) white blood cell (WBC) count >5 cells/μL [138][152]D.
- Supportive Features: Positive Kernig’s or Brudzinski’s signs, photophobia, and systemic inflammatory markers (e.g., elevated C-reactive protein or procalcitonin) [146]C[150]C.
- Exclusion Criteria: Alternative explanations for meningismus, such as (confirmed by CT or xanthochromia) or cervical spine pathology [146]C.
Infectious Differentials
Viral Meningoencephalitis
Viral etiologies are the most common cause of aseptic meningitis. While enteroviruses and herpes simplex virus (HSV) predominate, clinicians must consider regional and emerging viruses. (TBE) should be suspected in endemic areas; CSF findings typically show moderate pleocytosis (median 63 cells/μL) and elevated protein (median 0.61 g/L) [138]. Toscana virus (TOSV) is a significant cause of summer meningitis in the Mediterranean, often presenting with a benign course but requiring serological confirmation [48]C. In North America, Snowshoe hare virus (SSHV) and West Nile virus (WNV) are critical considerations, particularly in children and the elderly, respectively [47]C[141]C. WNV neuroinvasive disease may uniquely present with extrapyramidal symptoms or flaccid paralysis [141]C.
Atypical Bacterial and Rare Pathogens
- (GAS): Though rare (0.02–0.07 per 100,000), GAS meningitis carries a high case-fatality rate of 19.4%, significantly higher than S. pneumoniae [53]D.
- Mycoplasma hominis: Usually seen in neonates, this can cause CNS infection in adults following neurosurgery or in immunocompromised states [136].
- Salmonella enterica: A rare cause that may present with a thunderclap headache, mimicking subarachnoid hemorrhage [146]C.
- : Neuroleptospirosis can mimic primary viral meningitis; diagnosis requires PCR or microscopic agglutination tests (MAT) [98]D.
Parasitic and Amoebic Infections
Free-living amoebae, such as Naegleria fowleri (Primary Amoebic Meningoencephalitis, PAM) and Acanthamoeba (Granulomatous Amoebic Encephalitis, GAE), are nearly universally fatal and must be considered in patients with rapid progression and warm freshwater exposure [137][149]D. Neurocysticercosis remains a leading cause of acquired epilepsy and can present with meningeal signs if cysts rupture into the subarachnoid space [149]D.
Non-Infectious Mimics
Autoimmune Astrocytopathy and Encephalitis
GFAP astrocytopathy is a major mimic of infectious meningoencephalitis. It typically presents with subacute fever, headache, and encephalopathy [131]. A hallmark imaging finding is linear perivascular radial enhancement in the white matter [131][143]C. Similarly, Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) can present with acute coma or delirium, often requiring the exclusion of secondary infections like EBV or lymphoma [144]C[150]C.
Immune Reconstitution Inflammatory Syndrome (IRIS)
In patients with HIV and prior cryptococcal meningitis, the initiation of antiretroviral therapy (ART) can trigger neurological IRIS. This presents as a recurrence of meningitis symptoms despite negative fungal cultures, often showing migratory MRI patterns [133]C.
Diagnostic Algorithm
To efficiently narrow the differential, a systematic approach is required:
- Step 1: Clinical Stabilization and Screening: Assess for signs of increased intracranial pressure (ICP). Perform a non-contrast CT if focal deficits, papilledema, or new-onset seizures are present to rule out mass lesions or (found in 1.9% of bacterial cases) [41][146]C.
- Step 2: Lumbar Puncture (LP): Obtain CSF for cell count, protein, glucose, and culture. Crucial: 44.4% of patients receive before LP, which significantly reduces culture sensitivity [148]D.
- Step 3: Rapid Molecular Testing: Utilize multiplex PCR panels (e.g., BioFire FilmArray ME Panel) for 14 common pathogens. These provide results in ~1 hour and are cost-effective by reducing hospital stay [66][152]D.
- Step 4: Advanced Diagnostics: If initial tests are negative and suspicion remains high, employ metagenomic Next-Generation Sequencing (mNGS) for hypothesis-free pathogen detection [139]D[104]D. For suspected autoimmune cases, order serum and CSF autoantibody panels (e.g., GFAP-IgG, CASPR2) [131][151]C.
Imaging and Electrodiagnostics
While meningitis is primarily a clinical and laboratory diagnosis, imaging is vital for identifying complications and mimics.
- MRI: Preferred for detecting leptomeningeal enhancement, brain abscesses, or the linear perivascular enhancement characteristic of GFAP astrocytopathy [41][131].
- CT: Essential for detecting pneumocephalus (a rare complication of Citrobacter koseri) or acute hemorrhage [140]C[146]C.
- EEG: Indicated if encephalitis is suspected (e.g., in Cat Scratch Disease or WNV) to evaluate for subclinical seizures or status epilepticus, which occurs in up to 68% of CSD encephalitis cases [153]D[141]C.
| Condition | Key Clinical Feature | CSF Finding | Diagnostic Tool |
|---|---|---|---|
| Bacterial Meningitis | Acute onset, high fever, rigors | Neutrophilic pleocytosis, low glucose | Culture, Gram stain, PCR [152]D |
| Viral Meningitis | Subacute, photophobia | Lymphocytic pleocytosis, normal glucose | Multiplex PCR [66] |
| GFAP Astrocytopathy | Subacute, encephalopathy | Lymphocytic pleocytosis, high protein | CSF GFAP-IgG [131] |
| Brain Abscess | Focal deficit, headache | Often normal or mild pleocytosis | Contrast MRI [41] |
| Neuroleptospirosis | Systemic symptoms (jaundice, renal) | Lymphocytic pleocytosis | MAT, Blood/CSF PCR [98]D |
| PAM (Amoebic) | Rapidly fatal, water exposure | Hemorrhagic pleocytosis | CSF wet mount, PCR [137] |
| Test | Sensitivity | Specificity | Timing | Note |
|---|---|---|---|---|
| CSF Culture | Variable | High | 24–72 hours | Reduced by pre-LP antibiotics [148]D |
| Multiplex PCR | High (>90%) | High | ~1 hour | Detects 14 common pathogens [152]D |
| mNGS | High | High | 24–48 hours | Hypothesis-free; detects rare pathogens [139]D |
| Head CT | Low (for meningitis) | N/A | Minutes | Used to rule out mass/hemorrhage [146]C |
| MRI (Contrast) | High | Moderate | Hours | Best for GFAP and abscess [131][41] |
Management of Meningitis
- ▸Empiric antibiotics (e.g., Ceftriaxone 2 g + Vancomycin 15-20 mg/kg) must be administered within 60 minutes of presentation to reduce mortality.
- ▸Dexamethasone (0.15 mg/kg) should be given before or with the first antibiotic dose to mitigate the inflammatory response to bacteriolysis.
- ▸Tuberculous meningitis management may involve high-dose Rifampicin (35 mg/kg) and requires long-term steroid tapering based on clinical and potentially genetic factors.
The of is a medical emergency requiring rapid stabilization, immediate administration of empiric antimicrobials, and targeted adjunctive therapies to mitigate neuroinflammation. Delay in treatment is a primary driver of poor outcomes, particularly in bacterial and tuberculous forms where the host immune response often exacerbates brain injury [73]D[158].
Step 1: Initial Assessment and Severity Classification
Upon presentation, clinicians must immediately assess for signs of increased intracranial pressure (ICP) and systemic instability. In febrile infants ≤28 days, the PECARN prediction rule is utilized to identify those at low risk for invasive bacterial infection, though most guidelines still mandate routine lumbar puncture in this age group [60]. Severity is classified based on the Glasgow Coma Scale (GCS), presence of focal neurological deficits, and hemodynamic status. Patients with a GCS <12, respiratory distress, or rapidly progressing purpura should be managed in an Intensive Care Unit (ICU). Postoperative patients must be monitored closely; a delay in diagnosis beyond 7 days post-surgery is associated with significantly worse outcomes in postoperative bacterial meningitis (PBM) [158].
Step 2: Immediate Empiric Antimicrobial Therapy
Empiric therapy must be initiated within 60 minutes of arrival. Do not delay for neuroimaging if a lumbar puncture is deferred.
- Standard Bacterial Coverage: For most adults, Ceftriaxone 2 g IV every 12 hours plus Vancomycin 15-20 mg/kg IV every 8-12 hours is the standard.
- Listeria Coverage: Add Ampicillin 2 g IV every 4 hours for patients >50 years or those with immunocompromise.
- Neonatal Considerations: In neonates with invasive , regimens often require prolonged courses if complications like ventriculitis develop [86]C.
- Resistance Patterns: Global data indicate rising resistance in Streptococcus pneumoniae and Neisseria meningitidis, necessitating the inclusion of Vancomycin in empiric protocols until sensitivities are confirmed [35]. For pandrug-resistant organisms like Chryseobacterium gleum, Linezolid 600 mg IV every 12 hours has shown efficacy as an adjunctive option [160]C.
Step 3: Adjunctive Corticosteroid Administration
Dexamethasone 0.15 mg/kg IV every 6 hours should be administered 10-20 minutes before or concomitant with the first dose of antibiotics. This reduces the inflammatory response triggered by bacteriolysis [79]D. In (TBM), dexamethasone is recommended for 6-8 weeks, though its benefit may be genotype-specific. Research suggests that patients with the LTA4H TT genotype (hyperinflammatory) derive the most survival benefit, while those with CC or CT genotypes may have a more heterogeneous response [84].
Step 4: Pathogen-Specific Management
Once a pathogen is identified via culture or molecular methods (e.g., mNGS or tNGS), therapy should be narrowed [91]C[93]C.
- Tuberculous Meningitis (TBM): Standard therapy includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide. While high-dose Rifampicin (35 mg/kg/day) increases CNS penetration, meta-analyses of RCTs have not shown a definitive reduction in all-cause mortality compared to the standard 10 mg/kg/day dose, though it remains safe [31][59]. Novel oxazolidinones like Contezolid 800 mg PO twice daily are being evaluated as safer alternatives to Linezolid, showing adequate CSF penetration above the MIC for M. tuberculosis (0.5 μg/mL) [83][162]C.
- Fungal Meningitis: For cryptococcal meningitis in patients with advanced HIV, induction with Amphotericin B is standard. In pediatric CNS , adding IV Liposomal Amphotericin B (L-AmB) 5 mg/kg/day to Fluconazole 12 mg/kg/day is often necessary when fluconazole monotherapy fails [163]C.
- Viral and Aseptic: Viral meningoencephalitis (e.g., EBV) requires targeted antivirals like Acyclovir 10 mg/kg IV every 8 hours [91]C. If drug-induced aseptic meningitis (DIAM) is suspected (often due to NSAIDs or antibiotics), the offending agent must be discontinued immediately [61].
Step 5: Monitoring and Complication Management
Continuous monitoring for cerebral infarction is critical in TBM, as strokes significantly increase morbidity. Adjunctive antiplatelet therapy with Aspirin 75-150 mg daily or Clopidogrel 75 mg daily is often utilized to prevent ischemic events [156]. For refractory Gram-negative infections, intraventricular Polymyxin B (50,000 units daily) may be considered to achieve therapeutic CSF levels that systemic therapy cannot reach [164]C. In cases of immune reconstitution inflammatory syndrome (IRIS) following cryptococcal meningitis, individualized immunotherapy may be required [133]C.
| Drug | Typical Dose | Route | Key Indication | Evidence Level |
|---|---|---|---|---|
| Ceftriaxone | 2 g q12h | IV | Empiric bacterial coverage | 1a |
| Vancomycin | 15-20 mg/kg q8-12h | IV | Penicillin-resistant S. pneumoniae | 2a |
| Rifampicin | 10-35 mg/kg daily | PO/IV | Tuberculous meningitis | 1a [31] |
| Contezolid | 800 mg BID | PO | TBM (Linezolid alternative) | 1b [83] |
| Acyclovir | 10 mg/kg q8h | IV | Viral (HSV/EBV) meningitis | 4 [91]C |
| Polymyxin B | 50,000 units daily | Intraventricular | MDR Gram-negative pathogens | 4 [164]C |
Supportive Care and Complication Management
- ▸Neurological sequelae affect over 30% of meningitis survivors, necessitating formal audiological and cognitive follow-up.
- ▸CSF diversion (EVD/LD) is a critical adjunct for managing elevated ICP, even in the absence of hydrocephalus.
- ▸Paradoxical reactions and PIIRS require aggressive corticosteroid therapy to manage immune-mediated neurological deterioration.
The of acute meningitis extends beyond antimicrobial therapy to the aggressive stabilization of physiological derangements and the prevention of permanent neurological sequelae. Neurological complications affect more than 30% of survivors globally, often remaining underreported due to inadequate follow-up [33]. Effective supportive care requires a multi-disciplinary approach focusing on intracranial pressure (ICP) dynamics, seizure control, and the management of systemic inflammatory responses.
Step 1: Initial Assessment and Severity Classification
Upon admission, clinicians must classify the severity of meningitis to determine the appropriate level of care (ICU vs. ward). Severity is defined by the presence of altered consciousness, hemodynamic instability, or focal neurological deficits. In neonates, clinical signs are often non-specific; fever is present in only 57.4% and irritability in 42.6% of invasive meningococcal cases [86]C.
Risk Stratification for Hydrocephalus: In neonatal bacterial meningitis (NBM), early identification of hydrocephalus risk is critical for prognosis [180]D. Clinicians should monitor for signs of ventriculitis, which may necessitate prolonged antimicrobial courses and surgical consultation [86]C. In pediatric (TBM), disease stage at presentation is a primary determinant of outcome, often influenced by delays in diagnosis due to non-specific symptoms [178]D.
Step 2: Management of Elevated Intracranial Pressure (ICP)
Elevated ICP is a major driver of mortality and morbidity in severe meningitis [166]. While standard medical management (osmotic therapy, elevation) is first-line, CSF diversion techniques are essential adjuncts.
- External Ventricular Drainage (EVD) and Lumbar Drainage (LD): These are utilized to manage refractory intracranial even in the absence of overt hydrocephalus [166]. EVD allows for both pressure monitoring and therapeutic CSF removal, which can reduce the inflammatory burden within the subarachnoid space [166].
- Surgical Intervention for Hydrocephalus: In pediatric tuberculous meningitis-related hydrocephalus (TBMH), clinicians must choose between Endoscopic Third Ventriculostomy (ETV) and Ventriculoperitoneal Shunt (VPS) [167]. While VPS is traditional, ETV is advocated as a shunt-free alternative to mitigate long-term complications like shunt infection or malfunction [167]. A combination of multi-drug anti-tuberculosis therapy and VPS has been shown to successfully resolve critical cases of TBM with hydrocephalus [174]C.
Step 3: Seizure Control and Neuroprotection
Seizures are a frequent complication, occurring in 68% of patients with cat-scratch disease (CSD) encephalitis, with a significant proportion progressing to status epilepticus requiring mechanical ventilation [153]D.
- Protocol for Seizure Management:
- Immediate Stabilization: Administer benzodiazepines (e.g., Lorazepam 0.1 mg/kg IV) for active seizures.
- Maintenance: Initiate long-acting anticonvulsants (e.g., Levetiracetam or Phenytoin) if seizures recur or if the patient is at high risk due to cortical involvement on imaging [153]D.
- Monitoring: Continuous EEG is recommended in patients with altered mental status to detect non-convulsive status epilepticus.
Step 4: Management of Inflammatory and Paradoxical Reactions
In certain etiologies, the host immune response causes secondary damage after the initiation of effective antimicrobial therapy.
- Paradoxical Reactions (PR): Frequently observed in HIV-negative TBM, PR involves a selective immune upregulation and cytokine surge, leading to new or worsening neurological lesions despite microbiological response [40]. Management may require intensified immunosuppression.
- Post-Infectious Inflammatory Response Syndrome (PIIRS): In non-HIV patients with cryptococcal meningitis, PIIRS presents as neurological deterioration with sterile CSF [94]C. High-dose corticosteroids (e.g., Prednisone 1 mg/kg/day) are used to improve Karnofsky performance scores and reduce CNS inflammation [94]C.
- MOGAD and Autoimmune Mimics: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can present as meningoencephalitis, particularly in children, requiring differentiation from infectious causes to initiate appropriate immunotherapy [168]. Similarly, autoimmune GFAP astrocytopathy often mimics TBM, leading to misdiagnosis and delayed steroid treatment [175]C.
Step 5: Long-term Sequelae Monitoring and Transition
Survivors must undergo systematic screening for long-term deficits. Sensorineural hearing loss (SNHL) is a hallmark sequela; early detection is vital to prevent cognitive decline and social isolation [34].
- Audiological Protocol: Formal audiological diagnostic testing should be performed at discharge or shortly thereafter [34].
- Neuropsychiatric Follow-up: Patients should be screened for cognitive deficits and Paroxysmal Sympathetic Hyperactivity (PSH), an underacknowledged association in TBM characterized by autonomic instability [172]C.
- Shunt Monitoring: Patients with permanent shunts (e.g., LP shunts) require lifelong monitoring for infections, such as those caused by Corynebacterium striatum, which can lead to septic shock [67]C.
| Drug | Indication | Dose/Route | Evidence Level |
|---|---|---|---|
| Prednisone | PIIRS (Cryptococcal) | 1 mg/kg/day PO | 4 [94]C |
| Dexamethasone | Bacterial Meningitis | 0.15 mg/kg Q6H IV | 2a [166] |
| L-AmB | CNS Coccidioidomycosis | 3-5 mg/kg/day IV | 4 [163]C |
| Azathioprine | MUO (Inflammatory) | 2 mg/kg/day PO | 5 [165]D |
| Fluconazole | Fungal Meningitis | 400-800 mg/day PO/IV | 4 [163]C |
Prognosis and Long-term Outcomes
- ▸Neurological sequelae affect over **30%** of meningitis survivors, necessitating long-term audiological and cognitive follow-up.
- ▸The BUN/ALB ratio is a validated prognostic marker; higher ratios at admission correlate with unfavorable 3-month outcomes (mRS 3-6).
- ▸Cerebral infarction is a primary driver of morbidity in tuberculous meningitis, significantly worsening the functional prognosis.
The prognosis of acute meningitis is highly variable and depends primarily on the causative pathogen, the patient's age, and the speed of therapeutic intervention. Despite advances in antimicrobial therapy and molecular diagnostics, such as the panel [66], meningitis remains a significant cause of global morbidity and mortality. Neurological sequelae are estimated to affect more than 30% of survivors worldwide, though these are frequently underreported due to inadequate long-term follow-up [33].
Mortality and Recovery Statistics
Mortality rates remain high for specific etiologies. (TBM) is considered the most lethal form of tuberculosis; even with standard treatment, it is often fatal or results in severe disability [59]. In patients with , particularly those with HIV/AIDS, the disease accounts for approximately 19% of all AIDS-related deaths globally [184]D. Neonatal invasive , while rare, is associated with severe morbidity and high mortality rates [86]C. For bacterial meningitis, early identification of high-risk patients is critical, as unfavorable outcomes (defined as a score of 3–6) are common in those presenting with systemic complications [62].
Prognostic Factors and Scoring Systems
Several clinical and laboratory markers serve as independent predictors of outcome. The Blood Urea Nitrogen to Serum Albumin (BUN/ALB) ratio has emerged as a significant prognostic tool in bacterial meningitis. A high BUN/ALB ratio within 6 hours of admission is strongly associated with unfavorable 3-month outcomes [62]. In TBM, the presence of cerebral infarction on initial or follow-up MRI is a major predictor of poor functional recovery and increased mortality [156].
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Neurological Status | GCS 15 at presentation | Low GCS, focal deficits [3] |
| Laboratory (BUN/ALB) | Low ratio (< threshold) | High BUN/ALB ratio [62] |
| Imaging (MRI) | Normal or meningeal enhancement only | Cerebral infarction, hydrocephalus [156] |
| Pathogen | Viral (except WNV) | S. pneumoniae, M. tuberculosis [78]D[141]C |
| Host Factors | Immunocompetent | HIV/AIDS, neonatal age [184]D[86]C |
Long-term Neurological Sequelae
Survivors of acute meningitis often face a lifetime of neurological challenges. The most common deficits include (SNHL), motor impairments, and seizure disorders [33][34].
Sensorineural Hearing Loss (SNHL)
SNHL is a hallmark complication of bacterial meningitis. Early detection is vital to mitigate permanent deafness and subsequent cognitive decline or social isolation [34].
Protocol for Audiological Follow-up [34]:
- Step 1: Perform bedside hearing assessment during the acute hospitalization phase.
- Step 2: Conduct formal audiological testing (e.g., pure-tone audiometry or auditory brainstem response) as soon as the patient is stable and before or shortly after discharge.
- Step 3: Schedule repeat testing at 3 to 6 months post-discharge to detect delayed-onset hearing loss.
Cognitive and Neuropsychological Impact
Cognitive impairment is particularly prevalent in TBM survivors, affecting domains such as memory, attention, and executive function [182]. These deficits correlate with brain-based biomarkers and the severity of the initial inflammatory response [88]. In viral cases, such as neuroinvasive disease, patients may suffer from long-term extrapyramidal symptoms and significant functional disability [141]C.
Recovery Timeline and Recurrence
The recovery process extends far beyond the acute hospital stay. While some patients achieve full recovery within weeks, many require months or years of rehabilitation.
- Acute Phase (0–4 weeks): Focus on survival and of intracranial pressure (ICP). CSF diversion via external ventricular drainage (EVD) may be required in severe cases [166].
- Subacute Phase (1–6 months): Peak period for identifying neurological deficits. Approximately 80% of those who will regain independent walking do so by 6 months [3].
- Chronic Phase (>6 months): Focus on cognitive rehabilitation and monitoring for recurrence.
Recurrence is a specific risk in certain populations. In postoperative meningitis following skull base surgery, the duration of infection can be predicted using nomograms that consider factors like CSF leakage and surgical complexity [157]. In cryptococcal meningitis, survivors may experience Post-Infectious Inflammatory Response Syndrome (PIIRS) or Immune Reconstitution Inflammatory Syndrome (IRIS), leading to secondary neurological deterioration despite microbiological cure [94]C[133]C.
| Pathogen | Estimated Mortality | Common Long-term Sequelae |
|---|---|---|
| M. tuberculosis | High (often lethal) | Cognitive impairment, motor deficits, stroke [59][182] |
| Cryptococcus spp. | 19% (AIDS-related) | PIIRS, vision loss, persistent headache [184]D[94]C |
| N. meningitidis | Variable (High in neonates) | Hearing loss, skin scarring, limb loss [86]C |
| West Nile Virus | <1% (but high in neuroinvasive) | Extrapyramidal symptoms, fatigue [141]C |
Landmark Trials and Key Evidence
- ▸Single-dose liposomal amphotericin B (10 mg/kg) is now the preferred induction therapy for cryptococcal meningitis due to non-inferiority and reduced toxicity compared to multi-day regimens [201].
- ▸High-dose rifampicin (35 mg/kg) increases CSF drug exposure in TBM but has not yet demonstrated a definitive survival benefit in large-scale RCTs [31, 59].
- ▸Adjunctive dexamethasone reduces neurologic sequelae in pediatric bacterial meningitis [185] but may not provide a survival benefit in HIV-associated TBM [196].
The of meningitis has been shaped by large-scale randomized controlled trials (RCTs) that address the high mortality and morbidity associated with central nervous system infections. Evidence focuses on optimizing antimicrobial penetration, the role of adjunctive anti-inflammatory agents, and the development of simplified induction regimens for resource-limited settings.
Bacterial Meningitis and Adjuvant Corticosteroids
The use of corticosteroids in pediatric bacterial meningitis remains a cornerstone of therapy to mitigate inflammatory damage. A systematic review and meta-analysis of RCTs [185] demonstrated that adjunctive corticosteroids significantly reduce the risk of hearing loss and neurologic sequelae in children. While mortality benefits were less pronounced, the reduction in long-term disability supports the routine administration of dexamethasone alongside the first dose of [185].
(TBM): The Intensified Therapy Debate
TBM carries the highest mortality of all forms of tuberculosis, often exceeding 25-50%. Recent evidence has focused on whether increasing the dose of rifampicin, which has poor blood-brain barrier penetration at standard doses, improves outcomes.
The Rifampicin Dosing Trials
Standard rifampicin dosing (10 mg/kg) achieves low concentrations in the cerebrospinal fluid (CSF). The Meya et al. (2025) trial [59] and a meta-analysis of seven RCTs [31] evaluated high-dose oral rifampicin (35 mg/kg). Despite achieving significantly higher CSF concentrations [188][205], high-dose rifampicin did not significantly reduce all-cause mortality compared to standard dosing [31][59]. Pharmacokinetic studies confirm that while 35 mg/kg oral or 20 mg/kg intravenous rifampicin increases exposure (AUC), the clinical impact remains heterogeneous [204][205].
Adjunctive Dexamethasone in TBM
While dexamethasone is standard for TBM, its efficacy in specific populations has been questioned. The trial by Donovan et al. (2023) [196] found that adjunctive dexamethasone did not improve survival in HIV-positive adults with TBM. Furthermore, the LTA4H genotype may influence response; a phase 3 trial [84] investigated whether the TT genotype (hyperinflammatory) benefits more from steroids than the CC/CT genotypes, though placebo was not superior in the latter group [84].
Novel Agents and Antiplatelets
- Linezolid: The addition of linezolid 1200 mg/day (tapered to 600 mg) to intensified regimens is being explored for its superior CSF penetration [191][199].
- Contezolid: A novel oxazolidinone, contezolid, has shown CSF concentrations exceeding the MIC for M. tuberculosis (0.5 μg/mL) with a potentially improved safety profile compared to linezolid [83].
- Aspirin: Secondary analysis of the ACT-TBM trial [156] suggests that adjunctive aspirin or clopidogrel may reduce the incidence of cerebral infarction, a major cause of TBM morbidity, though it does not significantly alter overall mortality [156][199].
Cryptococcal Meningitis (CM): The AMBITION-cm Paradigm
For HIV-associated cryptococcal meningitis, the AMBITION-cm trial [201] revolutionized treatment by validating a simplified induction regimen.
AMBITION-cm Protocol (Single-Dose Liposomal Amphotericin B)
Step 1 → Administer a single high dose of liposomal amphotericin B (10 mg/kg) on Day 1 [201]. Step 2 → Combine with 14 days of oral flucytosine (100 mg/kg/day) and fluconazole (1200 mg/day) [201]. Step 3 → Transition to fluconazole maintenance therapy.
This regimen was found to be non-inferior to the previous 7-day intravenous standard and was associated with significantly fewer adverse events, such as anemia and electrolyte imbalances [201]. Further research into oral formulations, such as lipid nanocrystal (LNC) amphotericin B, suggests that entirely oral induction regimens may be feasible in the future [197].
Preventive Strategies and Vaccine Evidence
Vaccination remains the most effective tool for reducing the global burden of meningitis. The introduction of the Meningococcal A conjugate vaccine (PsA-TT) in the African meningitis belt has been highly successful [186]. Recent phase 3 trials have focused on pentavalent (NmCV-5) vaccines covering serogroups A, C, W, Y, and X, demonstrating non-inferiority to existing quadrivalent vaccines and providing broader protection [190][198].
In the context of HIV, the REALITY trial [206] demonstrated that enhanced infection prophylaxis, including fluconazole 100 mg/day for 12 weeks, significantly reduces mortality in patients with advanced HIV (CD4 < 100 cells/μL), largely by preventing cryptococcal disease [206].
| Trial | Year | Population | Intervention | Key Finding |
|---|---|---|---|---|
| AMBITION-cm [201] | 2022 | HIV+ Cryptococcal Meningitis | Single-dose L-AmB (10 mg/kg) + 14d Flucytosine/Fluconazole | Non-inferior to 7d IV AmB; safer profile |
| Meya et al. [59] | 2025 | Tuberculous Meningitis | High-dose Rifampicin (35 mg/kg) vs. Standard (10 mg/kg) | No significant difference in 6-month mortality |
| Donovan et al. [196] | 2023 | HIV+ Tuberculous Meningitis | Adjunctive Dexamethasone vs. Placebo | No survival benefit in HIV-positive adults |
| NmCV-5 Phase 3 [198] | 2023 | Healthy 2–29 year olds | Pentavalent MenACWYX vaccine | Non-inferior immunogenicity to quadrivalent vaccine |
| ACT-TBM [156] | 2026 | Tuberculous Meningitis | Adjunctive Aspirin or Clopidogrel | Reduced risk of cerebral infarction/stroke |
Special Populations
- ▸Neonatal meningitis requires a high index of suspicion as classic meningeal signs are often absent; PECARN rules and CSF procalcitonin are vital diagnostic adjuncts.
- ▸Cryptococcal meningitis in HIV is best managed with the AMBITION protocol (single-dose liposomal amphotericin B) to balance efficacy and toxicity.
- ▸High-dose rifampin (35 mg/kg) is utilized in tuberculous meningitis to overcome limited blood-brain barrier penetration.
of meningitis requires significant modification in specific patient cohorts due to variations in microbial etiology, altered immune responses, and unique pharmacological considerations. Clinicians must adapt diagnostic thresholds and therapeutic regimens for neonates, pregnant individuals, and the immunocompromised to mitigate high rates of morbidity and mortality [3][53]D[64]D.
Pediatrics and Neonates
Neonatal meningitis presents a diagnostic challenge as classic signs like nuchal rigidity are often absent. Instead, infants may present with non-specific symptoms such as fever, apnea, irritability, or poor feeding [86]C[102]D. In infants ≤ 28 days old, the Pediatric Emergency Care Applied Research Network (PECARN) prediction rule is utilized to identify those at low risk for invasive bacterial infection (IBI), though routine lumbar puncture (LP) remains the standard for most febrile neonates in this age bracket [60].
Diagnostic Considerations
- Urinalysis: Febrile infants ≤ 90 days with a positive urinalysis have a significantly higher risk of concurrent IBI, including meningitis, compared to those with negative results [44].
- CSF Biomarkers: Cerebrospinal fluid (CSF) procalcitonin has emerged as a useful marker for diagnosing meningitis in infants < 90 days, offering better diagnostic accuracy than traditional CSF parameters [210].
- Molecular Testing: The Xpert MTB/RIF Ultra assay is recommended for rapid detection of (TBM) and rifampicin resistance in children aged 0–9 years [213]. Additionally, Human Parechovirus A (PeV-A) should be considered in infants < 60 days presenting with meningoencephalitis or sepsis-like illness [102]D.
Pathogen-Specific Management
- (GAS): While rare, GAS meningitis carries a high case-fatality rate of 19.4%, particularly in children < 1 year [53]D.
- Citrobacter koseri: This pathogen is associated with neonatal brain abscesses and rare complications like pneumocephalus [140]C.
- Elizabethkingia: These multidrug-resistant gram-negative bacilli (e.g., E. anophelis) require specialized antibiotic selection as they are often resistant to standard β-lactams [214]C.
- Acinetobacter baumannii: For pediatric patients, sulbactam dosing must be optimized to achieve a target of 60% time above the MIC in the CSF, accounting for the degree of meningeal inflammation [101]D.
Prognosis
Survivors of neonatal meningitis, particularly those with invasive Group B Streptococcus (iGBS), are at risk for long-term neurodevelopmental impairments that may manifest as lower standardized school test scores between ages 8 and 15 [52]D. The Motor Optimality Score Revised (MOS-R) at 3–5 months of age can help predict neurodevelopmental outcomes at 12 months [208].
Pregnancy
In pregnancy, meningitis management must balance maternal efficacy with fetal safety. A primary concern is Lymphocytic Choriomeningitis Virus (LCMV), a rodent-borne pathogen that can cause severe congenital infections and neurological malformations [75]D. Seroprevalence studies indicate that pregnant women in high-risk urban areas may have IgG positivity rates near 2.4–2.7% [75]D.
Clinical Protocol for Suspected Meningitis in Pregnancy
- Step 1: Immediate stabilization and fetal monitoring.
- Step 2: Perform LP unless contraindicated; include viral PCR for LCMV if neurological malformations are noted on [75]D.
- Step 3: Initiate empiric (e.g., Ampicillin for Listeria coverage) and avoid teratogenic agents where possible.
- Step 4: Coordinate with obstetrics for delivery planning if the mother is near term or clinically unstable.
Immunocompromised (HIV-Associated)
Advanced HIV disease (AHD), defined by a CD4 count < 200 cells/µL, predisposes patients to opportunistic fungal and mycobacterial meningitis. Cryptococcal meningitis (CM) remains a leading cause of mortality in this group [211]D[215]D.
Cryptococcal Meningitis (CM)
Screening for cryptococcal antigen (CrAg) in patients with CD4 < 100 cells/µL is highly effective for reducing mortality [209]. High blood CrAg titers are strongly associated with concurrent CM and increased death risk [216]D.
- Induction Therapy: The AMBITION protocol, consisting of a single dose of liposomal amphotericin B (10 mg/kg) combined with 14 days of fluconazole (1200 mg/day) and flucytosine (100 mg/kg/day), is now preferred in many settings due to reduced toxicity compared to traditional 7-14 day amphotericin courses [39][215]D.
- Toxicity Mitigation: Lower-dose flucytosine (60 mg/kg/day) may be used to maintain efficacy while reducing hematologic toxicity [39].
- Co-infections: Presence of EBV or CMV in the CSF of CM patients is associated with higher 10-week mortality [38].
Tuberculous Meningitis (TBM)
Standard TBM treatment often fails due to poor CNS penetration of rifampin.
- High-Dose Rifampin: Increasing the daily dose of rifampin to 35 mg/kg (compared to the standard 10 mg/kg) is investigated to improve survival outcomes in both HIV-positive and HIV-negative adults [59].
- TB Prevention: In patients with AHD and CM, initiating ultra-short course TB preventive therapy (1 month of daily isoniazid and rifapentine, 1HP) is feasible and safe after the initial CM induction phase [155].
Immune Reconstitution Inflammatory Syndrome (IRIS)
Following the initiation of antiretroviral therapy (ART), patients may develop IRIS, a paradoxical worsening of symptoms. This can manifest as recurrent cortical encephalitis with migratory MRI patterns [133]C. Management often requires individualized immunotherapy or corticosteroids [133]C.
Immunocompromised (Non-HIV)
This population includes solid-organ transplant (SOT) recipients and those on long-term immunosuppression.
- Pathogens: Rare organisms like Campylobacter fetus can cause meningitis in post-liver transplant or splenectomy patients [212]C.
- Post-Infectious Inflammatory Response Syndrome (PIIRS): Non-HIV patients with CM may develop PIIRS, characterized by neurological deterioration despite negative fungal cultures [64]D[94]C. This syndrome is driven by a selective immune upregulation and often requires high-dose corticosteroid therapy to manage CNS inflammation [94]C.
| Population | Key Diagnostic Consideration | Treatment Modification |
|---|---|---|
| Neonates | CSF Procalcitonin & PECARN Rule [60][210] | Ampicillin + Cefotaxime/Gentamicin; Sulbactam for Acinetobacter [101]D |
| HIV-Positive | CrAg Screening (CD4 <100) [209] | AMBITION Protocol (Single-dose L-AmB 10 mg/kg) [215]D |
| TBM (Adults) | Xpert MTB/RIF Ultra [213] | High-dose Rifampin (35 mg/kg) [59] |
| Non-HIV Immunosuppressed | MRI for PIIRS [94]C | Corticosteroids for post-infectious inflammation [94]C |
Prevention and Screening
- ▸Conjugate vaccines (Hib, PCV, MenACWY) are the primary defense against bacterial meningitis, inducing T-cell-dependent immunity and herd protection.
- ▸Post-exposure prophylaxis with Rifampin, Ciprofloxacin, or Ceftriaxone is mandatory for close contacts of Neisseria meningitidis cases to eliminate nasopharyngeal carriage.
- ▸Maternal GBS screening at 36-37 weeks gestation is essential to prevent early-onset neonatal meningitis, though it does not impact late-onset disease.
Prevention strategies for have shifted from reactive outbreak to proactive, population-wide immunization and targeted chemoprophylaxis. The introduction of conjugate vaccines has fundamentally altered the of bacterial meningitis, significantly reducing the burden of type b (Hib) and Streptococcus pneumoniae [220][229]. However, the emergence of non-vaccine serotypes and the persistence of high-risk populations necessitate ongoing screening and secondary prevention protocols [225]D[234]D.
Primary Prevention: Immunization
Haemophilus influenzae type b (Hib)
The Hib conjugate vaccine is the cornerstone of preventing invasive Hib disease, which was once the leading cause of pediatric bacterial meningitis [220][225]D. Conjugate vaccines are preferred over pure polysaccharide vaccines because they induce a T-cell-dependent immune response, which is effective in infants and provides long-term immunological memory [220].
- High-Risk Groups: Vaccination is particularly critical for patients with functional or anatomic asplenia, sickle cell disease, or complement deficiencies, as these individuals are at the highest risk for invasive encapsulated bacterial infections [225]D.
- Clinical Reasoning: Inpatient administration of the Hib vaccine is recommended for unvaccinated high-risk patients identified during hospitalization to ensure immediate protection [225]D.
Streptococcus pneumoniae
Pneumococcal conjugate vaccines (PCV10, PCV13) have significantly reduced the incidence of pneumococcal meningitis (PM) globally [221][234]D. In Southern Vietnam, PM cases were most frequent in children under 1 year of age (58.7%), highlighting the need for early infant vaccination [221].
- Serotype Replacement: Continuous monitoring is required as serotype replacement occurs; for instance, in Mexico, the distribution of S. pneumoniae serotypes shifted following the introduction of PCV7 and PCV13 [234]D.
- Special Populations: Children with (CSF) leaks or cochlear implants remain at elevated risk for PM despite vaccination, often requiring specialized immunization schedules [51]D.
Neisseria meningitidis
Meningococcal vaccines are categorized by the serogroups they target (A, B, C, W, Y, and X). The development of the pentavalent vaccine (NmCV-5), which targets serogroups A, C, Y, W, and X, represents a major advancement for the African meningitis belt, where these serogroups are endemic [190][232]D.
- Travel and Pilgrimage: Vaccination with the quadrivalent MenACWY vaccine is mandatory for pilgrims attending the Hajj or Umrah in Saudi Arabia [46]. This is due to the high carriage rates of N. meningitidis in mass gatherings, which facilitates transmission of virulent strains like MenW:cc11 [46][237]D.
- Outbreak Management: During serogroup B outbreaks, the 4CMenB vaccine is utilized, though its effectiveness against rare genosubtypes (e.g., B:19-54) must be confirmed via bactericidal antibody assays [235]D.
Secondary Prevention: Post-Exposure Prophylaxis (PEP)
Secondary prevention aims to eliminate nasopharyngeal carriage in close contacts of patients with invasive meningococcal or Hib disease, thereby preventing secondary cases and further transmission.
Protocol for Meningococcal PEP
Close contacts include household members, childcare center contacts, and anyone directly exposed to the patient's oral secretions (e.g., through kissing or shared utensils) within 7 days before symptom onset.
- Step 1: Risk Assessment: Identify close contacts within 24 hours of the index case diagnosis.
- Step 2: Antibiotic Selection:
- Rifampin: 600 mg orally every 12 hours for 2 days (Adults). Rifampin is the traditional choice but requires multiple doses and interacts with many medications.
- Ciprofloxacin: 500 mg orally as a single dose (Adults). Preferred for its ease of administration, though resistance must be monitored.
- Ceftriaxone: 250 mg intramuscularly as a single dose (Adults). Preferred for pregnant patients.
- Step 3: Education: Advise contacts that PEP reduces but does not eliminate risk; they must still monitor for fever or rash.
Screening and Neonatal Prevention
Group B Streptococcus (GBS)
Streptococcus agalactiae (GBS) is the leading cause of neonatal meningitis globally [226]D. Prevention relies on maternal screening and intrapartum antibiotic prophylaxis (IAP).
- Screening: Pregnant women are screened for GBS colonization at 36 0/7 to 37 6/7 weeks of gestation via vaginal-rectal swab [226]D.
- Prevention Gap: While IAP has successfully reduced early-onset GBS disease (within the first 6 days of life), it has not decreased the incidence of late-onset GBS meningitis, for which no vaccine is currently available [226]D.
Vaccine-Related Considerations and Safety
Clinicians must balance the overwhelming benefits of vaccination against rare adverse events to maintain public trust and informed consent.
- Vaccination: Rare cases of aseptic meningitis and meningoencephalitis have been reported following COVID-19 vaccination (e.g., BNT162b2, mRNA-1273) [217][219][231]C. Symptoms typically include severe headache and fever, often resolving with corticosteroids like methylprednisolone [233]C.
- Varicella Vaccine: In rare instances, the live-attenuated varicella vaccine virus can reactivate years later in immunocompetent children, causing varicella vaccine meningitis [218]. The median age for this rare complication is 11 years [218].
- Malaria Vaccine (RTS,S): Early trials of the RTS,S/AS01E malaria vaccine showed a potential safety signal with an excess of meningitis cases in recipients [195][222]. However, large-scale pilot implementations in Ghana, Kenya, and Malawi have been used to further evaluate these risks alongside the vaccine's substantial impact on malaria-related mortality [195].
| Vaccine Type | Target Serogroups | Clinical Context/Indication | Key Evidence |
|---|---|---|---|
| MenACWY | A, C, W, Y | Mandatory for Hajj/Umrah pilgrims; routine adolescent dose | [46], [237]D |
| NmCV-5 (MenFive) | A, C, W, Y, X | Designed for the African Meningitis Belt; covers serogroup X | [190], [232]D |
| 4CMenB | B | Used in outbreaks; coverage depends on strain genosubtype | [235]D |
| PsA-TT | A | Eliminated Serogroup A epidemics in the African Meningitis Belt | [186] |
Guidelines and Resources
- ▸Tuberculous meningitis (TBM) is a medical emergency where empirical treatment must start before diagnostic confirmation to prevent high mortality [239, 258].
- ▸Definitive diagnosis of Lyme neuroborreliosis requires the triad of neurological symptoms, CSF pleocytosis, and intrathecal antibody production [257, 262].
- ▸Antibiotic initiation is recommended within 1 hour for suspected sepsis with shock and within 3 hours for sepsis without shock [240].
Clinical practice guidelines for meningitis emphasize rapid recognition, standardized diagnostic pathways, and the immediate initiation of antimicrobial therapy to mitigate the high rates of mortality and long-term disability associated with central nervous system (CNS) infections [239][248]. Recent updates, particularly in the of tuberculous and fungal meningitis, reflect a shift toward global consensus and evidence-based protocols tailored to resource-variable settings [239][242].
Bacterial and Community-Acquired Meningitis
Guidelines for community-acquired bacterial meningitis (ABM) prioritize the reduction of "door-to-needle" time. The European Federation of Neurological Societies (EFNS) and the UK Joint Specialist Societies emphasize that ABM is a medical emergency [248][259].
- Diagnostic Protocol: Patients should be rapidly hospitalized. While fast-track brain imaging is ideal before a (LP) to rule out mass effect, antibiotic therapy must not be delayed beyond 3 hours (or 1 hour if sepsis with shock is suspected) [240][259].
- Neonatal Standards: The GAIA group (Brighton Collaboration) provides standardized international definitions for neonatal meningitis to improve data collection and immunization safety monitoring [247].
- Surgical Prevention: For infants with myelomeningocele, the Congress of Neurological Surgeons recommends closure within 48 hours of birth to significantly decrease the risk of ventriculitis and subsequent meningitis [244].
Tuberculous and Fungal Meningitis
(TBM) remains the most lethal form of tuberculosis, prompting the Tuberculous Meningitis International Research Consortium (2026) to establish updated PICO-based guidance [239].
- Empirical Initiation: The British Infection Society mandates that empirical anti-tuberculosis therapy be started immediately upon suspicion; clinicians should not wait for microbiological or molecular confirmation, as delay is the strongest predictor of death [258].
- Cryptococcal Management: The 2024 Global Guideline (ECMM/ISHAM/ASM) provides a comprehensive framework for , covering screening in high-risk populations, induction therapy, and long-term follow-up care [242].
Neuroborreliosis and
Guidelines for tick-borne and sexually transmitted CNS infections have seen significant updates to refine diagnostic accuracy.
- Lyme Neuroborreliosis (LNB): The German S3 Guideline (2025) and EFNS (2010) define definite LNB based on three criteria: neurological symptoms, CSF pleocytosis, and intrathecal production of Borrelia burgdorferi-specific antibodies [257][262]. PCR is generally not recommended unless symptoms have lasted less than 6 weeks [257].
- Neurosyphilis: Recent Portuguese guidelines (2024) propose standardized monitoring for neurosyphilis, a "great imitator" that occurs in approximately 30% of untreated syphilis cases [268]. The USPSTF (2025) reaffirms the necessity of screening during pregnancy to prevent , which can manifest as neonatal meningitis [241].
Critical Care and Adjunctive Therapy
Management of complications such as and hydrocephalus is governed by neurocritical care standards.
- Cerebral Edema: The Neurocritical Care Society (2020) recommends hyperosmolar agents (mannitol or hypertonic saline) and corticosteroids for acute edema management, balancing the osmotic gradient benefits against risks of renal injury or fluid overload [243].
- Hydrocephalus: For premature infants with posthemorrhagic hydrocephalus, guidelines focus on optimal drainage strategies to prevent secondary infection and neurological decline [250].
Preventive Guidelines and Vaccination
Immunization remains the primary strategy for reducing the global burden of meningitis.
- Pneumococcal Vaccine: The ACIP (2010) recommends the 23-valent polysaccharide vaccine (PPSV23) for all adults aged ≥65 years and high-risk younger adults to prevent invasive pneumococcal disease [254].
- Meningococcal Vaccine: Recent updates (2020) advocate for the transition from monovalent C to tetravalent ACWY vaccines at age 12 [263].
- : In mass-casualty scenarios, the CDC (2015) provides a clinical framework for using medical countermeasures, including the anthrax vaccine and specific antimicrobials, to treat Bacillus anthracis meningitis [249][256].
| Guideline | Organization | Year | Key Recommendations |
|---|---|---|---|
| Tuberculous Meningitis | TBM Int. Research Consortium | 2026 | PICO-based diagnosis; immediate anti-TB chemotherapy and adjunctive anti-inflammatories [239]. |
| Lyme Neuroborreliosis | German S3 / AWMF | 2025 | Updated diagnostic criteria for polyradiculitis and meningitis; antibiotic protocols [262]. |
| Cryptococcosis | ECMM / ISHAM / ASM | 2024 | Global approach to screening, induction, and follow-up for fungal meningitis [242]. |
| Neurosyphilis | Portuguese Proposal | 2024 | Standardized diagnostic and monitoring approach for HIV-positive and negative patients [268]. |
| Cerebral Edema | Neurocritical Care Society | 2020 | Use of hyperosmolar therapy (Mannitol/HTS) and corticosteroids for ICP management [243]. |
| Acute ABM | UK Joint Specialist Societies | 2016 | Early recognition; standardized algorithm for community-acquired meningitis [248]. |
| Viral Encephalitis | ABN / BIA | 2012 | Rapid aciclovir initiation; delay >48h associated with poor prognosis [252]. |
References
- [1]
Håndstad M, Alaoui-Ismaili A, Juhler M et al.. “A systematic review of reviews on ventriculostomy related infection definitions: A fundamental problem.” Neurosurgical review (2025). PMID: 40069523 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [2]
Vaezipour N, Bigi S, Song R et al.. “Rifampicin and its neuroprotective properties in humans - A systematic review.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2025). PMID: 40024057 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Taweephol T, Pongpitakmetha T, Boonwan N et al.. “Clinical characteristics and factors associated with tuberculous meningitis outcomes in Thailand: A 13-year retrospective cohort study.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41173203 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors, Prognosis and Long-term Outcomes, Special Populations - [4]
Kane Y, Nalikka B, Tendu A et al.. “Genetic Diversity and Geographic Spread of Henipaviruses.” Emerging infectious diseases (2025). PMID: 40023785 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [5]
Long B, Gottlieb M. “Emergency medicine updates: Evaluation and diagnosis of sepsis and septic shock.” The American journal of emergency medicine (2025). PMID: 39892181 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [6]
Sultana S, Islam A, Ng J et al.. “Bat Reovirus as Cause of Acute Respiratory Disease and Encephalitis in Humans, Bangladesh, 2022-2023.” Emerging infectious diseases (2025). PMID: 41490742 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [7]
Vernygora O, Bourque L, Jones M et al.. “Novel Dolphin Tupavirus from Stranded Atlantic White-Sided Dolphin with Severe Encephalitis, Canada, 2024.” Emerging infectious diseases (2025). PMID: 41379633 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [8]
Zhu Z, Bao Y, Zhang Z et al.. “Emerging Neisseria meningitidis ST-1466 and ST-11026 as urogenital pathogens in China.” BMC infectious diseases (2025). PMID: 41162927 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [9]
Gass JT, Nofchissey RA, Twohig FM et al.. “Discovery of a novel lymphocytic choriomeningitis virus strain associated with severe human disease in immunocompetent patient, New Mexico.” Emerging microbes & infections (2025). PMID: 40838561 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors - [10]
Neri A, Taviani E, Ferraro F et al.. “Genomic analysis of Neisseria meningitidis serogroup W causing invasive meningococcal disease in four travellers from Saudi Arabia, Italy, 2025.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2025). PMID: 40776895 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [11]
Cherabuddi K, Tagliamonte MS, Lednicky JA et al.. “A Case Cluster of Aseptic Meningitis Associated With a Newly Identified Recombinant Echovirus 6/Coxsackievirus B1 Enterovirus.” The Journal of infectious diseases (2025). PMID: 40359283 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [12]
Garijo-Toledo M, Alarcón-Elbal PM, Montero E et al.. “Mortality associated with Angiostrongylus cantonensis in non-human primates in Europe.” International journal for parasitology (2025). PMID: 40194692 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [13]
Jiang Y, Yang J, Liu Y et al.. “A neonate with meningitis caused by probiotic-related Clostridium butyricum.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 40185197 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [14]
Ewing A, Haldeman S, Job MJ et al.. “Haemophilus influenzae Type b Meningitis in Infants, New York, New York, USA, 2022-2023.” Emerging infectious diseases (2025). PMID: 40023813 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [15]
Chiu CY, Godasi RR, Hughes HR et al.. “Two Human Cases of Fatal Meningoencephalitis Associated with Potosi and Lone Star Virus Infections, United States, 2020-2023.” Emerging infectious diseases (2025). PMID: 39983710 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [16]
Leiva-Ordoñez JE, Quintero B. “Diagnosis of Tuberculous Meningitis: Integrating Clinical Assessment and Molecular Diagnostics.” Diagnostics (Basel, Switzerland) (2026). PMID: 41750700 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [17]
Trejos Pino JV, Rodriguez Delgado JC. “Clinical Presentations and Nosocomial Infections of Neurolisteriosis.” The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale (2025). PMID: 40547324 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [18]
Ciftci E, Ocal D, Somer A et al.. “Current methods in the diagnosis of invasive meningococcal disease.” Frontiers in pediatrics (2025). PMID: 40330073 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [19]
Scheier TC, Tufa TB, Feldt T et al.. “Standard of care in advanced HIV disease: review of HIV treatment guidelines in sub-Saharan African countries-an extension study of eight countries.” AIDS research and therapy (2025). PMID: 40158188 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [20]
Zhu W, Shao L, Feng S et al.. “Tahyna virus: an emerging threat to public health.” Archives of virology (2025). PMID: 39928175 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [21]
Wu LL, Shi WD, Peng WF et al.. “Unraveling the interplay between meningitis and mitochondria: Etiology, pathogenesis, and therapeutic insights.” International immunopharmacology (2025). PMID: 39765004 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [22]
Kneubehl AR, Rehm DP, Curtis MW et al.. “Geographically Distinct Circulation of Genotype II and III St. Louis Encephalitis Virus, Texas, USA, 2009-2024.” Emerging infectious diseases (2026). PMID: 41986946 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [23]
Andrus PS, Han QC, Yang LM et al.. “Population genetic diversity of invasive Pomacea snails and surveillance of Angiostrongylus cantonensis in Shanghai, East China.” Parasites & vectors (2026). PMID: 41803893 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [24]
Yang H, Wang H, Han J et al.. “Emergence of a novel cefotaxime- and ciprofloxacin-resistant strain of serogroup Y Neisseria meningitidis sequence type 23 clonal complex in China.” The Journal of infection (2026). PMID: 41724334 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [25]
Gonzales BE, Durand D, Mercado EH et al.. “Genomic features of pneumococcal strains isolated from paediatric patients with invasive disease during pneumococcal conjugate vaccine introduction in Lima, Peru.” Microbial genomics (2026). PMID: 41632608 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [26]
Itani TM, Chalapa VI, Patrusheva AK et al.. “Genetic Diversity of the Non-Polio Enteroviruses Detected in Samples of Patients with Aseptic Meningitis in the Ural Federal District and Western Siberia.” Viruses (2026). PMID: 41600882 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [27]
Aparicio MT, Diop S, Mounier R. “Comments on: risk factors for nosocomial meningitis in patients with external ventricular drainages.” Journal of intensive care (2026). PMID: 41588552 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [28]
Andersen M, Haglund A, Murra M et al.. “Validation of the ICD-10 Diagnoses of Early-Onset Neonatal Infection in the Danish National Patient Register from 2010 to 2018.” Clinical epidemiology (2026). PMID: 41541820 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [29]
Fratty IS, Kriger O, Weiss L et al.. “Epidemiology of Enteroviruses Among Hospitalized Patients in Israel (2016-2024): CNS Involvement, Subtype Variability, and Seasonality.” Journal of medical virology (2026). PMID: 41540956 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [30]
Liao H, Li M, Zeng L et al.. “Molecular characterization of Neisseria meningitidis isolates from healthy individuals in Meigu County, Sichuan Province, 2021-2024.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41518555 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [31]
Pu J, Wu S, He JQ. “High dose of rifampicin in the treatment of tuberculous meningitis: a systematic review and meta-analysis of randomized controlled trials.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41511673 ↗
L1aSR_MA_RCTCited in: Epidemiology and Risk Factors, Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [32]
Matmat K, Jamann H, Maazouzi A et al.. “A multidimensional analysis of neuropsychiatric lupus: clinical, biological and imaging insights from systematic evidence.” Frontiers in immunology (2026). PMID: 41918728 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [33]
Alviz LF, Kim CY, Monette LE et al.. “Detection of sequelae from acute meningitis during clinical review by a healthcare provider: a systematic review and meta-analysis.” BMC medicine (2026). PMID: 41761295 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [34]
Alviz LF, Kim CY, Benevides-Tadinac AC et al.. “Detection of hearing loss by formal audiological testing after acute infectious meningitis: a global systematic review and meta-analysis.” BMC medicine (2026). PMID: 41761238 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, History and Physical Examination, Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [35]
Lazarus G, Caddey B, Dean A et al.. “Antimicrobial resistance in bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae (2010-24): a systematic review and meta-analysis.” The Lancet. Microbe (2026). PMID: 41616789 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Management - [36]
Onohuean H, Choonara YE. “Epidemiological distribution of bacterial meningitis infections in South Africa: a systematic review and meta-analysis.” BMC infectious diseases (2025). PMID: 41073968 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [37]
Akwetey SA, Osman AH, Kotey FCN et al.. “The epidemiology of infectious meningitis in Ghana: a systematic review and meta-analysis.” BMC public health (2025). PMID: 40770623 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [38]
Ellis J, Groppelli E, Doyle R et al.. “Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial.” The lancet. HIV (2025). PMID: 40915307 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Landmark Trials and Key Evidence, Special Populations - [39]
Rutakingirwa MK, Skipper CP, Dai B et al.. “Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2026). PMID: 40795226 ↗
L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors, Special Populations - [40]
Verma R, Chakraborty R. “A Clinico-Immunological Perspective of Paradoxical Reaction in HIV-ve Tuberculous Meningitis with Therapeutic Possibilities.” Neurology India (2025). PMID: 40705281 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Supportive Care and Complication Management, Special Populations - [41]
Liechti FD, Drost EHGM, Bijlsma MW et al.. “Brain Abscesses Complicating Bacterial Meningitis-A Nationwide Cohort Study From the Netherlands.” European journal of neurology (2026). PMID: 41738138 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Differential Diagnosis - [42]
Xu X, Su X, Li W et al.. “Clinical features and mortality risk factors in non-HIV elderly patients with cryptococcal meningitis: A retrospective cohort study from 2013 to 2022.” PLoS neglected tropical diseases (2025). PMID: 40934274 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [43]
Kim E, Hong J, Shin H et al.. “Prophylactic antibiotic use in closed basilar skull fractures: A nationwide cohort study.” The journal of trauma and acute care surgery (2026). PMID: 40857668 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [44]
Drummond H, Umana E, Mills C et al.. “Prevalence of invasive bacterial infection among febrile infants with positive urinalysis results: a planned secondary analysis of the Febrile Infants Diagnostic assessment and Outcome (FIDO) prospective observational cohort study.” Archives of disease in childhood (2025). PMID: 40628460 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, History and Physical Examination, Special Populations - [45]
He L, Yu M, Sun Z et al.. “Dynamic analysis of pathogenic distribution and drug resistance mechanism in neonatal suppurative meningitis: a retrospective study.” Italian journal of pediatrics (2025). PMID: 40604892 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [46]
Alhajaji R, Alfahmi M, Alamri SA et al.. “Neisseria Meningitidis Carriage Among Hajj and Umrah Pilgrims: A Systematic Review and Meta-Analysis.” European journal of medical research (2025). PMID: 40765002 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Prevention and Screening - [47]
Ali F, Imperial M, Morshed M et al.. “Pediatric Meningoencephalitis Cluster Caused by Snowshoe Hare Virus, Whistler, British Columbia, Canada, 2024.” Emerging infectious diseases (2026). PMID: 41986254 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors, Differential Diagnosis - [48]
Szojka ZI, Florian DM, Cabal A et al.. “Imported aseptic meningitis due to Toscana virus infection in Austria since 2006, including a case series from 2023.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41615838 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Diagnosis and Workup, Differential Diagnosis - [49]
Lagare A, Abdoulaye B, Thiaw FD et al.. “First detection of echovirus 18 associated with aseptic meningitis in a child in Niger Republic, 2024: a case report.” BMC infectious diseases (2025). PMID: 41126107 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors - [50]
Li Y, Zhang X, Wang M et al.. “Observation on the efficacy of Xiao Chai Hu Tang plus minus Tang combined with sodium valproate in the treatment of meningitis-associated epilepsy.” Pakistan journal of pharmaceutical sciences (2025). PMID: 40761063 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [51]
Levy C, Bizot E, Milcent K et al.. “Epidemiology and Characteristics of Bacterial Meningitis of Children with Cerebrospinal Fluid Leakage or Cochlear Implant.” Journal of the Pediatric Infectious Diseases Society (2026). PMID: 41800559 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Pathophysiology, History and Physical Examination, Diagnosis and Workup, Prevention and Screening - [52]
Lykke MR, Sørensen HT, Lawn JE et al.. “School performance following invasive Group B Streptococcus disease in early infancy in Denmark.” Annals of epidemiology (2026). PMID: 41643755 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Special Populations - [53]
Hawkins PA, Chochua S, Prasad N et al.. “Group A Streptococcus Meningitis, United States, 1997-2022.” Emerging infectious diseases (2026). PMID: 41612532 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis, Special Populations - [54]
André A, Brière O, Bourreau L et al.. “Risk factors for acute kidney injury associated with intravenous acyclovir in older adults: ACICLOAGED study.” Maturitas (2026). PMID: 41604824 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis - [55]
Mehl C, Schmidt-Chanasit J, Becker-Ziaja B et al.. “Lymphocytic Choriomeningitis Virus Seroprevalence in a Cohort of German Forestry Workers.” Viruses (2025). PMID: 41600769 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [56]
Anjum SH, Hargarten J, Dulek B et al.. “Cerebral Venous Thrombosis in Previously Healthy Patients with Cryptococcal Meningitis.” The Journal of infectious diseases (2026). PMID: 41443253 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [57]
Mesele DW, Kalayu AA, Teshome S et al.. “Enhanced detection of bacterial etiologies, antibiotic resistance profile, and treatment outcomes of meningitis patients in Ethiopia: a prospective cross-sectional study.” BMC microbiology (2025). PMID: 41387772 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [58]
Lambebo IH, Eba K, Tucho GT. “Association between climatic conditions and infectious diseases: implications for Central Ethiopia region.” BMC infectious diseases (2025). PMID: 41331557 ↗
L5OTHERCited in: Epidemiology and Risk Factors, History and Physical Examination - [59]
Meya DB, Cresswell FV, Dai B et al.. “Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis.” The New England journal of medicine (2025). PMID: 41406445 ↗
L1bRCTCited in: Etiology and Triggering Factors, Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence, Special Populations - [60]
Burstein B, Waterfield T, Umana E et al.. “Prediction of Bacteremia and Bacterial Meningitis Among Febrile Infants Aged 28 Days or Younger.” JAMA (2026). PMID: 41359314 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors, History and Physical Examination, Management, Special Populations - [61]
Singh MP, Yadav R, Singh J. “Drug-Induced Aseptic Meningitis: A 25-Year Systematic Review of Case Reports.” Clinical neuropharmacology (Unknown). PMID: 41529234 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors, Pathophysiology, Management - [62]
Liang A, Zhang Y, Li X et al.. “Association of the blood urea nitrogen to serum albumin ratio on prognosis in patients with bacterial meningitis: a retrospective cohort study.” Frontiers in cellular and infection microbiology (2026). PMID: 41929452 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes - [63]
Dzięgiel M, Głodowicz Z, Jóźwiak A et al.. “Bacterial meningitis in adults: therapeutic challenges in the era of antibiotic resistance and the potential of bacteriophages and associated by products.” Frontiers in cellular and infection microbiology (2026). PMID: 41728112 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Management - [64]
Scott TL, Quezado M, Williamson PR. “Update on the diagnosis, pathophysiology and treatment strategies in non-HIV-associated cryptococcal meningoencephalitis.” Expert review of anti-infective therapy (2026). PMID: 41661810 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology, Special Populations - [65]
Shi Y, Liang T, Shi C et al.. “Molecular mechanisms of streptococcal disruption of the blood-brain barrier and their pathogenic role in bacterial meningitis.” Frontiers in immunology (2025). PMID: 41573555 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology - [66]
Churcher LM, Bartlett AW, Pendle S et al.. “Impact of the BioFire FilmArray Meningitis-Encephalitis Panel on Management of Suspected Paediatric Central Nervous System Infections: A Single-Centre Retrospective Cohort Study.” Journal of paediatrics and child health (2026). PMID: 41652807 ↗
L2bCOHORTCited in: Etiology and Triggering Factors, Pathophysiology, Diagnosis and Workup, Differential Diagnosis, Prognosis and Long-term Outcomes - [67]
Maeda A, Hayashi K, Izumi R et al.. “Lumbar-peritoneal shunt-associated meningitis and peritoneal abscess due to Corynebacterium striatum: A case report and literature review.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2026). PMID: 41391636 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Supportive Care and Complication Management - [68]
Ba A, Wang L, Ren R et al.. “Purulent meningitis in X-linked agammaglobulinemia: one case report.” Frontiers in immunology (2026). PMID: 41988175 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [69]
Hariswar PT, Mahathi G, Praveenkumar T et al.. “Clinical Reasoning: A 49-Year-Old Man With Meningoencephalitis and Persistent Altered Mental Status.” Neurology (2026). PMID: 41771008 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, History and Physical Examination, Diagnosis and Workup - [70]
Grant A, Keegan S, Kulasegaram R. “Role of long-acting injectables in perinatally acquired HIV, with persistent viraemia and non-nucleoside reverse transcriptase inhibitor resistance.” Sexually transmitted infections (2026). PMID: 41545056 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Diagnosis and Workup, Management, Special Populations - [71]
Li XF, Ker A, Liao HL et al.. “Adult-onset Still's disease presenting with aseptic meningitis: a case report.” Frontiers in immunology (2025). PMID: 41476957 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Management, Supportive Care and Complication Management - [72]
Krebs L, Durden B, Saguil A. “Aseptic and Bacterial Meningitis: Diagnosis, Treatment, and Prevention.” American family physician (2026). PMID: 41839077 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology - [73]
Tucker EW, Kim J, Erice C et al.. “Host-directed nanotherapy for the treatment and imaging of tuberculous meningitis.” Theranostics (2026). PMID: 41993622 ↗
L5OTHERCited in: Etiology and Triggering Factors, Pathophysiology, Diagnosis and Workup, Management - [74]
Pircher H, Thomas OS, Haefke AS et al.. “Increased Constitutive Interferon-β Levels and Altered CD4 T Cell Homeostasis Induced by Expression of a Viral Glycoprotein.” European journal of immunology (2026). PMID: 41972454 ↗
L5OTHERCited in: Etiology and Triggering Factors - [75]
Flannery DD, Cossaboom CM, Flietstra TD et al.. “Lymphocytic Choriomeningitis Virus Seroprevalence among Urban Pregnant Women and Newborns, Philadelphia, Pennsylvania, USA, 2021.” Emerging infectious diseases (2026). PMID: 41863505 ↗
L5OTHERCited in: Etiology and Triggering Factors, Special Populations - [76]
Kansas GS. “Transient loss of KLF2 expression is essential for CD8 effector T cell expansion.” Journal of immunology (Baltimore, Md. : 1950) (2026). PMID: 41847849 ↗
L5OTHERCited in: Etiology and Triggering Factors, Diagnosis and Workup - [77]
Wang Y, Liu H, Wang Y et al.. “Biosynthesis of a Polysaccharide-based Glycoconjugate Vaccine against Neonatal Meningitis-Causing Escherichia coli O45.” ACS synthetic biology (2026). PMID: 41779879 ↗
L5OTHERCited in: Etiology and Triggering Factors, Prevention and Screening - [78]
George LS, Chakraborty A, Gupta S et al.. “Implementation of India's largest sentinel surveillance for meningitis: an exploratory qualitative analysis of the facilitators and challenges in this sentinel site network.” Frontiers in public health (2026). PMID: 41778120 ↗
L5OTHERCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes, Prevention and Screening - [79]
Lux J, Erhardt M, Rechsteiner L et al.. “Synthetic peptide V11A reduces bacterial load and inflammation in pneumococcal meningitis.” Frontiers in cellular and infection microbiology (2025). PMID: 41737843 ↗
L5OTHERCited in: Etiology and Triggering Factors, Management - [80]
Charmoy M, Maier JM, Wyss T et al.. “Memory-like CD8+ T cells lacking PD-1 adapt to persistent stimulation by reducing TCR signal transduction rather than increasing exhaustion.” Frontiers in immunology (2026). PMID: 41727489 ↗
L5OTHERCited in: Etiology and Triggering Factors - [81]
Yabumoto T, Sugiyama S, Hosokawa A et al.. “Viral load and pathophysiology-based framework in varicella-zoster virus meningitis: Focus on altered consciousness and outcomes.” Journal of the neurological sciences (2026). PMID: 41690184 ↗
L5OTHERCited in: Etiology and Triggering Factors, History and Physical Examination - [82]
Wollenweber ML, Beyrer K, Baillot A et al.. “The Meningitis and Encephalitis Registry of Lower Saxony, Germany (MERIN) - design and main results of circulating neurotropic pathogen surveillance, 2003 to 2023.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2026). PMID: 41684324 ↗
L5OTHERCited in: Etiology and Triggering Factors, Differential Diagnosis, Special Populations - [83]
Huang M, Wang Y, Chen T et al.. “Evaluation of contezolid's cerebrospinal fluid concentration and safety in tuberculous meningitis patients.” Microbiology spectrum (2026). PMID: 41823550 ↗
L1bRCTCited in: Pathophysiology, Diagnosis and Workup, Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [84]
Donovan J, Duc Bang N, Dong HKT et al.. “Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.” Nature medicine (2026). PMID: 41540106 ↗
L1bRCTCited in: Pathophysiology, Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [85]
Santiago IB, da Silva AA, Nóbrega ILP et al.. “Leukodystrophy-like phenotype in early-onset neuropsychiatric systemic lupus erythematosus: Case series and systematic review of the literature.” Revue neurologique (2026). PMID: 41638970 ↗
L2aSR_OBSCited in: Pathophysiology, Diagnosis and Workup, Supportive Care and Complication Management - [86]
Muyidi AA, Al-Zaydani IA, Alzahrani SJ et al.. “Neonatal invasive meningococcal disease: Clinical case from Saudi Arabia and updated review of reported cases.” Journal of infection and public health (2026). PMID: 41894900 ↗
L4CASE_REPORTCited in: Pathophysiology, Diagnosis and Workup, Management, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [87]
Luo Y, Guo Y, Zhu Y et al.. “Differentiating scrub typhus meningitis from brucellar meningitis in children: A single-center retrospective study.” PLoS neglected tropical diseases (2026). PMID: 41824464 ↗
L2bCOHORTCited in: Pathophysiology, Diagnosis and Workup - [88]
Chouksey SS, Singh VK, Chaurasia RN et al.. “Neurocognitive Outcomes and Their Correlation with Brain-Based Biomarkers in Tuberculous Meningitis: A Prospective Study.” The American journal of tropical medicine and hygiene (2026). PMID: 41666470 ↗
L2bCOHORTCited in: Pathophysiology, Diagnosis and Workup, Prognosis and Long-term Outcomes - [89]
Wong EWN, Chan CF, Chan PS. “Ocular Manifestations of Biopsy-Proven B Virus Infection with Central Nervous System Involvement.” JAMA ophthalmology (2026). PMID: 41712248 ↗
L4CASE_REPORTCited in: Pathophysiology, Diagnosis and Workup - [90]
Bao Y, Zhang W, Liu X et al.. “Case Report: Complete remission of Guillain-Barré syndrome in neuropsychiatric lupus with telitacicept.” Frontiers in immunology (2026). PMID: 41659868 ↗
L4CASE_REPORTCited in: Pathophysiology, Diagnosis and Workup, Management, Prognosis and Long-term Outcomes - [91]
Yang X, Li Z, Dai X et al.. “Streptococcus pyogenes and EBV coinfection in severe adult meningoencephalitis: a rare diagnosis in a diabetic patient.” Frontiers in cellular and infection microbiology (2025). PMID: 41625152 ↗
L4CASE_REPORTCited in: Pathophysiology, Diagnosis and Workup, Management - [92]
Ye R, Guo K, Zhou D et al.. “Misdiagnosed tuberculous myelitis turned out to be spinal malignant peripheral nerve sheath tumor: a case report.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41521307 ↗
L4CASE_REPORTCited in: Pathophysiology - [93]
Liu F, Sun S, Zhang Y et al.. “Possible tuberculous meningitis presenting with predominant voiding dysfunction in an elderly patient: A case report.” Journal of infection and public health (2026). PMID: 41505815 ↗
L4CASE_REPORTCited in: Pathophysiology, Management - [94]
Ito Y, Hoeltermann TA, Anjum S et al.. “Corticosteroid Therapy and Long-Term Outcomes of Post-Infectious Inflammatory Syndrome in Non-HIV Immunosuppressed Cryptococcal Meningitis: A Multicenter Case Series.” The Journal of infectious diseases (2026). PMID: 41486473 ↗
L4CASE_REPORTCited in: Pathophysiology, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations - [95]
Nagata W, Ishizuka T. “Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation.” Human cell (2026). PMID: 41989680 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [96]
Demirtzoglou G, Damanaki A, Flouda S et al.. “Unique brain mechanisms in early events in SLE with diffuse neuropsychiatric disease (NPSLE): Implications for the management.” Lupus (2026). PMID: 41831216 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [97]
Butler HM, Zehntner ME, Van Beusecum JP. “Endothelial Dysfunction: Insights into Systemic Lupus Erythematosus-associated Cardiovascular Disease and Neuropsychiatric Manifestations.” Journal of cardiovascular translational research (2026). PMID: 41795008 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [98]
Perera N, Gunawardena C, Abeyratne V et al.. “Neuroleptospirosis in patients presenting with primary central nervous system infection: A multicentre study.” PLoS neglected tropical diseases (2026). PMID: 41945620 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Differential Diagnosis, Supportive Care and Complication Management - [99]
Molloy CT, Alwarawrah Y, Cohen JA et al.. “Irgm1 Restrains CD8+ T Cell Cytokine Production and Apoptosis via Cell-Extrinsic Regulation of Type I Interferon Signaling.” European journal of immunology (2026). PMID: 41906618 ↗
L5OTHERCited in: Pathophysiology - [100]
Matmat K, Guéant-Rodriguez RM, Darcq E et al.. “IFNγ-associated immune-metabolic remodeling is linked to serotonin-kynurenine imbalance and cortical vulnerability in lupus-prone mice.” Frontiers in immunology (2026). PMID: 41869319 ↗
L5OTHERCited in: Pathophysiology - [101]
Onita T, Ikawa K. “Cerebrospinal Pharmacokinetic and Pharmacodynamic Evaluation of Sulbactam: Dosing Considerations for Acinetobacter baumannii Meningitis in Pediatric Patients.” Journal of the Pediatric Infectious Diseases Society (2026). PMID: 41810872 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Management, Special Populations - [102]
Yovel G, Packard JE, Wang JC et al.. “Neonatal CNS Human Parechovirus Infections in Western Pennsylvania in the 2024 Season.” Journal of medical virology (2026). PMID: 41810583 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Special Populations - [103]
Chen J, Cui C, Xu F et al.. “ShenQi DiHuang Decoction (SQDHD) Ameliorates Neuroinflammation and Neuropsychiatric Manifestations in Pristane Induced Lupus Mice via Blocking JAK1-STAT3 Pathway.” CNS neuroscience & therapeutics (2026). PMID: 41795136 ↗
L5OTHERCited in: Pathophysiology - [104]
Shean RC, Tardif KD, Rangel A et al.. “Evaluation of the Ultima Genomics UG 100 sequencer for low-cost, high-sensitivity metagenomic pathogen detection from cerebrospinal fluid.” Microbiology spectrum (2026). PMID: 41778823 ↗
L5OTHERCited in: Pathophysiology, Diagnosis and Workup, Differential Diagnosis - [105]
Twito NA, Röthlisberger AB. “Retrospective evaluation of leflunomide as second-line immunosuppressive therapy in dogs with meningoencephalomyelitis of unknown origin: 18 cases (2018-2025).” Journal of veterinary internal medicine (2026). PMID: 41742594 ↗
L5OTHERCited in: Pathophysiology, Prognosis and Long-term Outcomes - [106]
Aguilera C, Subah GD, Bogle C et al.. “Utility of Bone Cement for Cranioplasty Following Retrosigmoid or Translabyrinthine Craniectomy: A Systematic Review and Meta-Analysis.” Neurosurgical review (2025). PMID: 41254416 ↗
L2aSR_OBSCited in: History and Physical Examination - [107]
Khan K, Wilson P, Patel MS et al.. “A Systematic Review and Meta-Analysis of Meningitis Risk Reduction After Repair of Spontaneous Lateral Skull Base Cerebrospinal Fluid Leaks.” Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology (2025). PMID: 41039648 ↗
L2aSR_OBSCited in: History and Physical Examination - [108]
Julio PR, Capello CH, de Amorim JC et al.. “Chorea associated with systemic lupus erythematosus- a systematic review.” Lupus (2025). PMID: 40390391 ↗
L2aSR_OBSCited in: History and Physical Examination - [109]
Deniz M, Erat T, Arı HF et al.. “Evaluation of children with acute central nervous system infections admitted to the pediatric intensive care unit and pediatric ward: a retrospective study.” BMC pediatrics (2024). PMID: 39587526 ↗
L2bCOHORTCited in: History and Physical Examination - [110]
Pantalone MR, De Luca F, Terling L et al.. “Candida meningitis in three patients who underwent transsphenoidal surgery from a single-institution case series.” Acta neurochirurgica (2026). PMID: 41826722 ↗
L4CASE_REPORTCited in: History and Physical Examination - [111]
Yuan X, Fang M, Lan W et al.. “From urinary tract infection to deafness: community-acquired meningitis in an adult caused by hypervirulent Klebsiella pneumoniae-a case report.” BMC infectious diseases (2025). PMID: 41390369 ↗
L4CASE_REPORTCited in: History and Physical Examination - [112]
Goh WGW, Ng IKS, Tan MKX et al.. “Clinical Reasoning: A 26-Year-Old Woman With Headache and Eosinophilia.” Neurology (2025). PMID: 39983059 ↗
L4CASE_REPORTCited in: History and Physical Examination - [113]
Willis ZI, Buonsenso D. “Management of Young Infants With Incomplete Evaluation for Meningitis.” Journal of the Pediatric Infectious Diseases Society (2026). PMID: 41670340 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination, Special Populations - [114]
Lovund IK, Mjelle AB, Thaulow CM et al.. “Bacterial Meningitis in Norwegian Children 2010-2023: Low Incidence but Still a Major Threat in Neonates.” Acta paediatrica (Oslo, Norway : 1992) (2026). PMID: 41273196 ↗
L5OTHERCited in: History and Physical Examination - [115]
Krongsut S, Srithanabout P, Pansaksiri S et al.. “A new diagnostic model for the early differentiation of tuberculous and bacterial meningitis to guide timely diagnosis and treatment: Model development and internal validation.” Journal of infection and public health (2025). PMID: 41076850 ↗
L5OTHERCited in: History and Physical Examination - [116]
Nguyen THP, Young BR, Bornstein LM et al.. “Prevalence of Serious Infection Among Hypothermic Young Infants Across Medical Settings.” Hospital pediatrics (2025). PMID: 40947113 ↗
L5OTHERCited in: History and Physical Examination - [117]
Tang R, Mao S, Gu Y et al.. “A Nomogram Model to Predict Meningitis Occurrence in Cerebrospinal Fluid Leak Patients.” The Laryngoscope (2026). PMID: 40923621 ↗
L5OTHERCited in: History and Physical Examination - [118]
Aronson PL, Mahajan P, Meeks HD et al.. “Prediction Rule to Identify Febrile Infants 61-90 Days at Low Risk for Invasive Bacterial Infections.” Pediatrics (2025). PMID: 40854562 ↗
L5OTHERCited in: History and Physical Examination - [119]
Tang Y, Huang P, Xu J et al.. “Comprehensive analysis of disease activity, neuropsychiatric symptoms, imaging features and risk factors for seizure in hospitalized patients with juvenile-onset neuropsychiatric systemic lupus erythematosus.” Seminars in arthritis and rheumatism (2025). PMID: 40784140 ↗
L5OTHERCited in: History and Physical Examination - [120]
Fischer JL, Gallagher TJ, Lin ME et al.. “Complications in Endoscopic Sinus Surgery: A TriNetX Network Analysis.” International forum of allergy & rhinology (2025). PMID: 40782144 ↗
L5OTHERCited in: History and Physical Examination - [121]
Doka Hélène KS, Ignatius E, Berinyuy M et al.. “Nonsurgical Neurological Emergencies in Children: A Cross-Sectional Study of Prevalence, Diagnosis, and Management.” Pediatric neurology (2025). PMID: 40609287 ↗
L5OTHERCited in: History and Physical Examination - [122]
Urmenyi LG, Vinhaes CL, Villalva-Serra K et al.. “Influence of HIV co-infection on clinical presentation and disease outcome in hospitalized adults with tuberculous meningitis in Brazil: a nationwide observational study.” Frontiers in public health (2025). PMID: 40589807 ↗
L5OTHERCited in: History and Physical Examination - [123]
Aronson PL, Mahajan P, Nielsen B et al.. “Risk of Bacterial Infections in Febrile Infants 61 to 90 Days Old With Respiratory Viruses.” Pediatrics (2025). PMID: 40506050 ↗
L5OTHERCited in: History and Physical Examination - [124]
Steele JL, Smith HJ, Takkoush S et al.. “Long-Term Outcomes of Adult Temporal Bone Fractures With Hearing Loss: Results of a Multinational Database Analysis.” The Laryngoscope (2025). PMID: 40202220 ↗
L5OTHERCited in: History and Physical Examination - [125]
Yaeger JP, Hill EL, Ertefaie A et al.. “A Population-Based Study of Rates of Invasive Bacterial Infection (IBI) and Missed IBI in Febrile Infants 8-90 Days of Age.” The Journal of pediatrics (2025). PMID: 40199453 ↗
L5OTHERCited in: History and Physical Examination - [126]
Kameda S, Yamana H, Sasabuchi Y et al.. “Early Corticosteroid Use and Short-Term Outcomes in Pediatric Bacterial Meningitis: A Nationwide Study in Japan, 2014 to 2022.” Pediatric neurology (2025). PMID: 39892022 ↗
L5OTHERCited in: History and Physical Examination - [127]
Liu H, Kong X, Zeng Y et al.. “From pain to meningitis: bacteria hijack nociceptors to promote meningitis.” Frontiers in immunology (2024). PMID: 39877376 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [128]
Yaeger JP, Fiscella KA. “Variability in Invasive Bacterial Infection Proportions Among Febrile Infants Aged 8-90 Days Using Administrative Data.” Academic pediatrics (2025). PMID: 39577560 ↗
L5OTHERCited in: History and Physical Examination - [129]
Chessa E, Congiu F, Rizzo G et al.. “Rationale for investigating the use of anifrolumab in neuropsychiatric systemic lupus erythematosus: a combined narrative and case-based systematic literature review.” Frontiers in immunology (2026). PMID: 41756273 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [130]
Nouroozi F, Kazemi HS, Alinezhad A et al.. “Artificial Intelligence-based detection of neuropsychiatric lupus: an exploratory meta-analysis of neuroimaging and multimodal biomarker models.” Clinical and experimental medicine (2026). PMID: 41627551 ↗
L2aSR_OBSCited in: Diagnosis and Workup - [131]
Uawithya E, Siriphiphatcharoen P, Benjapibal B et al.. “Clinical, imaging, and immunological features of GFAP astrocytopathy: a systematic review with regional comparison.” Multiple sclerosis and related disorders (2026). PMID: 41576641 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Differential Diagnosis - [132]
Zhao L, He J, Mei C et al.. “The efficacy of rituximab plus telitacicept in neuropsychiatric systemic lupus erythematosus: A retrospective study.” Clinical immunology (Orlando, Fla.) (2026). PMID: 41708039 ↗
L2bCOHORTCited in: Diagnosis and Workup, Management, Prognosis and Long-term Outcomes - [133]
Wang W, Tang S, Yang J et al.. “Individualized immunotherapy for immune reconstitution-associated cortical encephalitis in an HIV-positive cryptococcal meningitis patient: a case report.” Frontiers in immunology (2026). PMID: 41983125 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Differential Diagnosis, Management, Prognosis and Long-term Outcomes, Special Populations - [134]
Ogawa T, Yamashiro K, Tsutsumi S et al.. “IgG4-related hypertrophic pachymeningitis presenting with marked dural thickening, widespread white matter changes, and rectus gyrus transdiaphragmatic herniation into the sella turcica: a case report.” Frontiers in immunology (2026). PMID: 41756303 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [135]
Jain S, Dayal R, Kamal R et al.. “Comparative analysis of diagnostic efficacy of loop-mediated isothermal amplification (LAMP) and CBNAAT in children with suspected tubercular meningitis: a cross-sectional study.” BMJ paediatrics open (2026). PMID: 41850741 ↗
L5OTHERCited in: Diagnosis and Workup - [136]
Gao X, Guo Y, Luo P et al.. “Central nervous system infection caused by Mycoplasma hominis in an adult: a case report and literature review.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 40788590 ↗
L2aSR_OBSCited in: Differential Diagnosis - [137]
Chaúque BJM, Chagas LB, da Silva TCB et al.. “Promising Drug Repurposing Candidates Targeting Free-Living Amoebae: A Systematic and Critical Review of Laboratory-Based Evidence.” Pathogens (Basel, Switzerland) (2026). PMID: 41901747 ↗
L2aSR_OBSCited in: Differential Diagnosis - [138]
Bogovič P, Kastrin A, Trampuš Bakija A et al.. “Cerebrospinal fluid findings and their temporal pattern in patients with different clinical presentations of tick-borne encephalitis; a cohort study.” Infection (2026). PMID: 41307887 ↗
L2bCOHORTCited in: Differential Diagnosis - [139]
López N, Cuesta G, Puerta-Alcalde P. “Viral meningoencephalitis: a focus on diagnostics.” Current opinion in infectious diseases (2025). PMID: 40990729 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [140]
Di Maria S, Bolcato M, Concato M et al.. “Hospital-Acquired Citrobacter Meningitis Complicated by Pneumocephalus in a Neonate.” Pediatrics (2026). PMID: 41734809 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Supportive Care and Complication Management, Special Populations - [141]
Marín-Cruz I, López-Lobato M, Falcón-Neyra D et al.. “Emergence of Pediatric West Nile Virus Neuroinvasive Disease in Spain: An Expanding Threat in a Changing Climate-A Case Series.” The Pediatric infectious disease journal (2026). PMID: 41361685 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Prognosis and Long-term Outcomes - [142]
Nguyen LCA, Nguyen PMA, Nguyen THN. “Human herpesvirus 7 induced aseptic meningitis in an immunocompetent adult presenting with unusual neurological symptoms: a case report.” Virology journal (2025). PMID: 41299705 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Supportive Care and Complication Management - [143]
Lin Y, Diao Z, Low J et al.. “Therapeutic efficacy of telitacicept in a patient with GFAP autoimmune astrocytopathy: a case report.” Frontiers in immunology (2025). PMID: 41181139 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Prognosis and Long-term Outcomes - [144]
Zhang Y, Zheng S, Li Y et al.. “Case Report: A case of neuropsychiatric lupus with primary central nervous system diffuse large B-cell lymphoma.” Frontiers in immunology (2025). PMID: 40918104 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [145]
Yang J, Zhang F, Guo X et al.. “Human herpesvirus type 4 combined with Brucella abortus meningitis case report.” BMC infectious diseases (2025). PMID: 40855467 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [146]
El-Baba M, Austin E. “Thunderclap headache in a patient with Salmonella Enterica meningitis.” The American journal of emergency medicine (2025). PMID: 40603211 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [147]
Lopez C, Sanchez-Sanchez R, Corona D et al.. “A Fatal Case of Monkeypox-Associated Encephalitis in a Non-HIV-Infected Patient.” Critical care explorations (2025). PMID: 40505032 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [148]
Ramirez J, Furmanek S, Chandler T et al.. “A Ten-Year Retrospective Review of Medical Records of Patients Admitted with Meningitis or Encephalitis at Five Hospitals in the United States Highlights the Potential for Under-Ascertainment of Invasive Meningococcal Disease.” Pathogens (Basel, Switzerland) (2025). PMID: 41156573 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [149]
Shahrivar F, Moghimi A, Hosseinzadeh R et al.. “A comprehensive review on the neurological impact of parasitic infections.” Microbial pathogenesis (2025). PMID: 40446972 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [150]
Pang L, Xu X, Liu Y et al.. “A case report and literature review of neuropsychiatric lupus presenting with coma as the initial symptom.” Medicine (2026). PMID: 41560092 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [151]
Gao P, Chen X, Li Y et al.. “Anti-CASPR2 meningoencephalitis with thickened dura mater induced by various infections: A case report and literature review.” Medicine (2025). PMID: 40550065 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [152]
Veljanoska E, Szende A, McGill F et al.. “Cost implications of introducing the BIOFIRE FILMARRAY meningitis/encephalitis panel vs. real-time PCR in adult and pediatric populations in the UK.” Journal of medical economics (2026). PMID: 41608961 ↗
L5OTHERCited in: Differential Diagnosis - [153]
Yakubovsky M, Kadar L, Katchman E et al.. “Cat scratch disease encephalitis: New insights into rate, clinical features, and long-term outcomes.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41544843 ↗
L5OTHERCited in: Differential Diagnosis, Supportive Care and Complication Management - [154]
Nassur JA, Schnell KM, Dolon CD et al.. “Epidemiology of healthcare-associated ventriculitis and meningitis (HCAVM) and community-acquired meningitis/encephalitis and evaluation of an off-label PCR panel for HCAVM diagnosis.” Microbiology spectrum (2026). PMID: 41451990 ↗
L5OTHERCited in: Differential Diagnosis - [155]
Ellis J, Hale G, Nsangi LJ et al.. “Inpatient initiation of tuberculosis preventive therapy with 1 month of isoniazid and rifapentine for adults with advanced HIV disease and cryptococcal meningitis (IMPROVE): a non-inferiority, randomised controlled trial.” The lancet. HIV (2026). PMID: 41662846 ↗
L1bRCTCited in: Management, Landmark Trials and Key Evidence, Special Populations - [156]
Chandu M, Bhatia R, Modi M et al.. “Patterns and Factors Associated With Cerebral Infarction on MRI in Tuberculous Meningitis: Secondary Analysis of the ACT-TBM Trial.” Stroke (2026). PMID: 41521897 ↗
L1bRCTCited in: Management, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [157]
Yuan R, Peng H, Wang Y et al.. “Prognostic nomogram for predicting postoperative meningitis duration in skull base tumor surgery: a retrospective cohort study.” Journal of neurosurgery (2026). PMID: 41349019 ↗
L2bCOHORTCited in: Management, Prognosis and Long-term Outcomes - [158]
Peng H, Yuan R, Zheng Y et al.. “Delayed diagnosis in postoperative bacterial meningitis: A retrospective study in the skull base neoplasm surgery.” Clinical neurology and neurosurgery (2026). PMID: 41317437 ↗
L2bCOHORTCited in: Management - [159]
Smith D, Garikipati R, Bastug K et al.. “Paenibacillus dendritiformis as a Cause of Destructive Meningitis in Infants.” NEJM evidence (2026). PMID: 41632684 ↗
L4CASE_REPORTCited in: Management - [160]
Wang L, Bi Y, Zhou Y et al.. “Meningitis due to pandrug resistant Chryseobacterium gleum: microbiological cure and clinical response with linezolid-based combination therapy.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2026). PMID: 41483390 ↗
L4CASE_REPORTCited in: Management, Prognosis and Long-term Outcomes - [161]
Ariza-Varón M, Jaramillo-Arrázola MJ, Riveros L et al.. “Meningitis caused by Fusobacterium nucleatum complicated with cavernous sinus thrombosis: A case report.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41330476 ↗
L4CASE_REPORTCited in: Management, Prognosis and Long-term Outcomes - [162]
Liu W, He T, Qin H et al.. “Concentration of contezolid in cerebrospinal fluid and serum in a patient with renal allograft tuberculosis and tuberculous meningoencephalitis.” BMC infectious diseases (2025). PMID: 41257614 ↗
L4CASE_REPORTCited in: Management - [163]
Maran K, Adams R, Khan A et al.. “Intravenous Liposomal Amphotericin as an Adjunct to Fluconazole in Pediatric Patients With Central Nervous System Coccidioidomycosis: A Single-Center Case Series.” Journal of the Pediatric Infectious Diseases Society (2025). PMID: 41217140 ↗
L4CASE_REPORTCited in: Management, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [164]
Jiang H, Hu Y, Cai J et al.. “Variations in ventricular distribution of polymyxin B following intraventricular administration in patients with central nervous system infections.” Antimicrobial agents and chemotherapy (2026). PMID: 41196281 ↗
L4CASE_REPORTCited in: Management - [165]
Diop S, Van Caenegem N, Troupel T et al.. “Combination of azathioprine and prednisolone as a treatment for meningoencephalomyelitis of unknown origin in dogs: 54 cases.” Journal of veterinary internal medicine (2026). PMID: 41742501 ↗
L5OTHERCited in: Management, Supportive Care and Complication Management - [166]
Kilgore MD, Carr C, Kuchar M et al.. “Utility of lumbar and external ventricular drainage in the management of meningitis: a systematic review.” Neurosurgical focus (2025). PMID: 41175399 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [167]
Fagundes W, Ahmed AR, Silva YP et al.. “Endoscopic third ventriculostomy versus ventriculoperitoneal shunt for treating pediatric tuberculous meningitis hydrocephalus: a systematic review and meta-analysis.” Journal of neurosurgery. Pediatrics (2025). PMID: 40479834 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [168]
Tang X, Zhang W, Zhou A et al.. “Clinical, imaging, and recurrence analysis of myelin oligodendrocyte glycoprotein antibody-associated disease with initial presentation as meningoencephalitis in children: a single-center retrospective study.” Pediatric radiology (2025). PMID: 40464908 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [169]
Liu L, Wang X, Guo L et al.. “Epidemiological characteristics and disease burden of bacterial meningitis in hospitalized children in China: a 6-year nationwide retrospective study.” BMC infectious diseases (2025). PMID: 40275150 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [170]
Hsu CH, Hsuan YT, Chan YJ et al.. “Clinical presentation of cytomegalovirus meningoencephalitis: a retrospective study of 12 adult patients with a variety of immunocompromised conditions.” BMC infectious diseases (2025). PMID: 40264020 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [171]
Aletayeb SMH, Dehdashtian M, Aramesh MR et al.. “Ten-year review of hospital-acquired neonatal meningitis in a tertiary-level NICU: the important role of acinetobacter species.” BMC infectious diseases (2025). PMID: 40259250 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [172]
Datta A, Vardhan MV, Srivastava C. “Paroxysmal sympathetic hyperactivity in tubercular meningitis: An underacknowledged association.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2025). PMID: 41284088 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [173]
Li C, Liu M, Ji Y et al.. “Clinical characteristics and prognostic indicators in Listeria monocytogenes meningoencephalitis: A retrospective case series and literature review.” BMC neurology (2025). PMID: 41087940 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [174]
Sheng C, Wang M, Bao Q et al.. “Anti-tuberculosis therapy combined with ventriculoperitoneal shunt for tuberculous meningitis combined with hydrocephalus: A case report.” Journal of infection and public health (2025). PMID: 40763461 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [175]
Wu C, Han X, Yang F et al.. “Misdiagnosis of autoimmune glial fibrillary acidic protein astrocytopathy as infectious meningitis: a case report.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40439829 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [176]
Wang X, Liang L, Liang Y et al.. “A rare case of multiple brain abscesses caused by Nocardia abscessus co-infection with tuberculous meningitis in an immunocompetent patient.” BMC infectious diseases (2025). PMID: 40360973 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [177]
Sedgwick AK, Anderson S. “Acute Mastoiditis Complicated by Meningitis: A Case Report and Condition Overview.” Critical care nurse (2025). PMID: 41319997 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [178]
Plaatjie ON, van Furth AMT, Solomons R et al.. “Characterization of CSF tryptophan metabolites in South African children with tuberculous meningitis.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2026). PMID: 41260406 ↗
L5OTHERCited in: Supportive Care and Complication Management - [179]
Lempinen L, Saat R, Laulajainen-Hongisto A et al.. “Otogenic meningitis in children.” Infection (2026). PMID: 41247662 ↗
L5OTHERCited in: Supportive Care and Complication Management - [180]
Tianrui Y, Lingyun B, Jin G. “Establishment of a risk prediction model for hydrocephalus complicated by neonatal bacterial meningitis.” BMC infectious diseases (2025). PMID: 41013354 ↗
L5OTHERCited in: Supportive Care and Complication Management - [181]
Lin Q, Fang W, Fan K et al.. “A novel diagnostic strategy of differential diagnosis of tuberculous meningitis and non-tuberculous meningitis: a retrospective observational cohort study.” Microbiology spectrum (2026). PMID: 41313026 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [182]
Ashwin JV, Verma R, Shahi MK et al.. “Cognitive impairment in tuberculous meningitis: Systematic review & meta-analysis.” The Indian journal of tuberculosis (2026). PMID: 41831920 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [183]
Wang H, Ye S, Sun F. “Comparison of obinutuzumab and rituximab for treating neuropsychiatric lupus: a retrospective case-control study.” Lupus science & medicine (2025). PMID: 41193185 ↗
L3bCASE_CONTROLCited in: Prognosis and Long-term Outcomes - [184]
Walker RS, Vallejos GB, Nurye T et al.. “An analysis of national guidelines for the prevention, diagnosis and treatment of cryptococcal meningitis in sub-Saharan African countries: gaps and opportunities.” BMJ global health (2026). PMID: 41714099 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [185]
Tian C, Jin S, Zhao Z et al.. “Association of Corticosteroid Treatment With Outcomes in Pediatric Patients With Bacterial Meningitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Clinical therapeutics (2022). PMID: 35272859 ↗
L1aSR_MA_RCTCited in: Landmark Trials and Key Evidence - [186]
Hodgson A, Haidara FC, Sow SO et al.. “Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.” Vaccine (2025). PMID: 40966979 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Prevention and Screening - [187]
Calderin JM, Wasserman S, Resendiz-Galvan JE et al.. “Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.” Antimicrobial agents and chemotherapy (2025). PMID: 40590723 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [188]
Abdelgawad N, Wasserman S, Gausi K et al.. “Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis.” The Journal of infectious diseases (2025). PMID: 40295169 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [189]
Samuels THA, Molloy SF, Lawrence DS et al.. “Personalised risk-prediction tools for cryptococcal meningitis mortality to guide treatment stratification in sub-Saharan Africa: a prognostic modelling study based on pooled analysis of two randomised controlled trials.” The Lancet. Global health (2025). PMID: 40288401 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [190]
Diallo F, Haidara FC, Tapia MD et al.. “Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.” Lancet (London, England) (2025). PMID: 40086461 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Prevention and Screening - [191]
Chow FC, Kafeero P, Nakimbugwe M et al.. “Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults With Human Immunodeficiency Virus.” The Journal of infectious diseases (2025). PMID: 39960851 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [192]
Ibnou Zekri Lassout N, Goyal V, Krantz E et al.. “Bioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitis.” Clinical and translational science (2024). PMID: 39291723 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [193]
Meya DB, Nalintya E, Skipper CP et al.. “Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV-Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2025). PMID: 39044381 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [194]
Ahmed T, Tauheed I, Hoque S et al.. “A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY vaccine 'Ingovax ACWY' among Bangladeshi adults.” Vaccine (2024). PMID: 38897895 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Prevention and Screening - [195]
Asante KP, Mathanga DP, Milligan P et al.. “Feasibility, safety, and impact of the RTS,S/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.” Lancet (London, England) (2024). PMID: 38583454 ↗
L1bRCTCited in: Landmark Trials and Key Evidence, Prevention and Screening - [196]
Donovan J, Bang ND, Imran D et al.. “Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults.” The New England journal of medicine (2023). PMID: 37819954 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [197]
Boulware DR, Atukunda M, Kagimu E et al.. “Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 37606364 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [198]
Haidara FC, Umesi A, Sow SO et al.. “Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.” The New England journal of medicine (2023). PMID: 37224196 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [199]
Davis AG, Wasserman S, Stek C et al.. “A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023). PMID: 36482216 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [200]
Kelentse N, Moyo S, Choga WT et al.. “High concordance in plasma and CSF HIV-1 drug resistance mutations despite high cases of CSF viral escape in individuals with HIV-associated cryptococcal meningitis in Botswana.” The Journal of antimicrobial chemotherapy (2022). PMID: 36322466 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [201]
Jarvis JN, Lawrence DS, Meya DB et al.. “Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.” The New England journal of medicine (2022). PMID: 35320642 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [202]
Paradkar MS, Devaleenal D B, Mvalo T et al.. “Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022). PMID: 35291004 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [203]
Ngan NTT, Thanh Hoang Le N, Vi Vi NN et al.. “An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis.” eLife (2021). PMID: 34581270 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [204]
Wasserman S, Davis A, Stek C et al.. “Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.” Antimicrobial agents and chemotherapy (2021). PMID: 33972248 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [205]
Cresswell FV, Meya DB, Kagimu E et al.. “High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021). PMID: 33693537 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [206]
Pett SL, Spyer M, Haddow LJ et al.. “Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.” AIDS (London, England) (2021). PMID: 33306556 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [207]
Soul JS, Bergin AM, Stopp C et al.. “A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures.” Annals of neurology (2021). PMID: 33201535 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [208]
Dixon S, Ashby S, Kuhne C et al.. “The motor optimality of infants who have had Meningitis in the first months of life: A retrospective study.” Early human development (2026). PMID: 41506216 ↗
L2bCOHORTCited in: Special Populations - [209]
Govender NP, Greene GS, Hullsiek KH et al.. “Effectiveness of a National Reflex Laboratory Cryptococcal Antigen Screening Program for People With Advanced HIV Disease in South Africa: A Nationwide-Sampled Cohort Study (CAST-NET).” Journal of acquired immune deficiency syndromes (1999) (2025). PMID: 40663428 ↗
L2bCOHORTCited in: Special Populations - [210]
Krishnegowda VK, Bandiya P, Nanda D et al.. “Cerebrospinal Procalcitonin for Diagnosing Meningitis in Infants Less Than 90 Days: A Systematic Review and Meta-analysis.” Indian pediatrics (2025). PMID: 41060555 ↗
L2aSR_OBSCited in: Special Populations - [211]
Falconer J, Mmotsa TM, Govender NP et al.. “Diagnosis of cryptococcal meningitis in people living with HIV in low-income countries: barriers and strategies.” Expert review of anti-infective therapy (2025). PMID: 40874873 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [212]
Kitaya S, Otani H, Yanagi M et al.. “Campylobacter fetus meningitis and bacteremia: A case report in a post-liver transplant and post-splenectomy patient and a restructured literature review.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2025). PMID: 41241280 ↗
L4CASE_REPORTCited in: Special Populations - [213]
Kay AW, Madison M, Scandrett K et al.. “Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children.” The Cochrane database of systematic reviews (2025). PMID: 41128098 ↗
L2aSR_OBSCited in: Special Populations - [214]
Al Reesi MS, Muttawa LAA, Albolushi MA et al.. “Elizabethkingia Infections - An Important Emerging Cause of Sepsis and Meningitis in Neonates and Infants: Case Series from North Batinah Region, Oman, and literature review.” Sultan Qaboos University medical journal (2025). PMID: 40979593 ↗
L4CASE_REPORTCited in: Special Populations - [215]
Clark D, Barranco-Trabi J, Goo I et al.. “Single-Dose Liposomal Amphotericin Plus Fluconazole and Flucytosine for Cryptococcal Meningitis at a US Public Hospital.” JAMA network open (2026). PMID: 41563759 ↗
L5OTHERCited in: Special Populations - [216]
Mwamba TM, Blasich NP, Coetzee LM et al.. “Cryptococcal antigen titers and semi-quantitative assay scores among people with HIV-associated cryptococcal antigenemia.” Journal of clinical microbiology (2026). PMID: 41537580 ↗
L5OTHERCited in: Special Populations - [217]
Atefi A, Ghanaatpisheh A, Ghasemi A et al.. “Meningitis after COVID-19 vaccination, a systematic review of case reports and case series.” BMC infectious diseases (2024). PMID: 39390499 ↗
L2aSR_OBSCited in: Prevention and Screening - [218]
Ramachandran P, Grose C. “Serious neurological adverse events in immunocompetent children and adolescents caused by viral reactivation in the years following varicella vaccination.” Reviews in medical virology (2024). PMID: 38658176 ↗
L2aSR_OBSCited in: Prevention and Screening - [219]
Taiyeb Khosroshahi M, Hamidi S, Kangari P et al.. “Post-COVID-19 Vaccination Meningitis and Meningoencephalitis: A Systematic Review of Case Series and Case Reports.” The American journal of tropical medicine and hygiene (2025). PMID: 39437771 ↗
L2aSR_OBSCited in: Prevention and Screening - [220]
Tripathi N, Mukherjee S. “Efficacy and Prolonged Safety of Haemophilus influenzae Type b Conjugate Vaccines.” Infectious disorders drug targets (2024). PMID: 38231056 ↗
L2aSR_OBSCited in: Prevention and Screening - [221]
Truong HC, Phan TV, Nguyen HT et al.. “Clinical features and antibiotic resistance in pediatric pneumococcal meningitis in Southern Vietnam, 2012-2023: A multicenter retrospective study.” Journal of infection and public health (2025). PMID: 40318609 ↗
L2bCOHORTCited in: Prevention and Screening - [222]
Asante KP, Bozonnat MC, Savic M et al.. “Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S/AS01E malaria vaccine from 2016 to 2022.” The Lancet. Global health (2025). PMID: 40288396 ↗
L2bCOHORTCited in: Prevention and Screening - [223]
Bjar N, Hermansson A, Gisselsson-Solen M. “How common is otogenic meningitis? A retrospective study in southern Sweden over 18 years.” Infection (2024). PMID: 38416397 ↗
L2bCOHORTCited in: Prevention and Screening - [224]
Anosike C, Ojiakor IM, Etiaba EI et al.. “Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review.” Vaccine (2025). PMID: 41110197 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [225]
Ewing A, Haldeman S, Ratner AJ. “Clinical progress note: Haemophilus influenzae type b.” Journal of hospital medicine (2025). PMID: 40205699 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [226]
Alexander NG, Cutts WD, Hooven TA et al.. “Mechanisms and Manifestations of Group B Streptococcus Meningitis in Newborns.” Journal of the Pediatric Infectious Diseases Society (2025). PMID: 39927629 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [227]
Xu Y, Wang J, Qin X et al.. “Advances in the pathogenesis and treatment of pneumococcal meningitis.” Virulence (2024). PMID: 39192572 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [228]
Gil-Prieto R, Hernandez-Barrera V, Marín-García P et al.. “Hospital burden of pneumococcal disease in Spain (2016-2022): A retrospective study.” Human vaccines & immunotherapeutics (2025). PMID: 39786144 ↗
L2bCOHORTCited in: Prevention and Screening - [229]
Park JJ, Tiefenbach J, Anwar MM et al.. “Estimating the Global and Regional Burden of Streptococcus pneumoniae Meningitis in Children: Protocol for a Systematic Review and Meta-Analysis.” JMIR research protocols (2024). PMID: 39012685 ↗
L2aSR_OBSCited in: Prevention and Screening - [230]
Mikami S, Ishii M, Yano T et al.. “Multifocal meningoencephalitis after vaccination against COVID-19.” Pathology international (2024). PMID: 39570102 ↗
L4CASE_REPORTCited in: Prevention and Screening - [231]
Kim JH, Yoon D, Ko HY et al.. “Risk of encephalitis and meningitis after COVID-19 vaccination in South Korea: a self-controlled case series analysis.” BMC medicine (2024). PMID: 38486297 ↗
L4CASE_REPORTCited in: Prevention and Screening - [232]
Alderson MR, Regan K, Martellet L et al.. “Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond.” Human vaccines & immunotherapeutics (2025). PMID: 40968077 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [233]
Kato Y, Osada T, Araki N et al.. “Aseptic Meningitis after BNT-162b2 COVID-19 Vaccination: Case Report and Literature Review.” The Keio journal of medicine (2023). PMID: 37743529 ↗
L4CASE_REPORTCited in: Prevention and Screening - [234]
Carnalla-Barajas MN, Soto-Noguerón A, Solórzano-Santos F et al.. “Pneumococcal meningitis in Mexico. Serotype distribution and antimicrobial resistance before and after the introduction of pneumococcal conjugate vaccines in pediatric patients. Results from the GIVEBPVac group.” Journal of infection and public health (2026). PMID: 41223711 ↗
L5OTHERCited in: Prevention and Screening - [235]
Abad R, Navarro C, García-Amil C et al.. “Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B expressing a rare porA genosubtype (19-54, 15), Spain, March to April 2024.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2025). PMID: 41199706 ↗
L5OTHERCited in: Prevention and Screening - [236]
Kang MS, Lee SH, Jung SI et al.. “Shift from Streptococcus pneumoniae to Klebsiella pneumoniae: a 15-year nationwide study of bacterial meningitis in Korea.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41076061 ↗
L5OTHERCited in: Prevention and Screening - [237]
Campbell H, Lucidarme J, Clark SA et al.. “Increase in serogroup W invasive meningococcal disease in England associated with pilgrimage to Saudi Arabia, January 2024 to June 2025.” Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin (2025). PMID: 40776896 ↗
L5OTHERCited in: Prevention and Screening - [238]
Lee IG, Lee J, Kim HR et al.. “Galectin-4 potentiates CD8+ T cell immunity by enhancing MHC-I expression on dendritic cells.” Molecular therapy : the journal of the American Society of Gene Therapy (2025). PMID: 40589087 ↗
L5OTHERCited in: Prevention and Screening - [239]
Donovan J, Cresswell FV, Tucker EW et al.. “A clinical practice guideline for tuberculous meningitis.” The Lancet. Infectious diseases (2026). PMID: 40840485 ↗
L1cGUIDELINECited in: Guidelines and Resources - [240]
Malmgren A, Orfanos I, Smedbäck J et al.. “The Swedish Society of Paediatric Infectious Diseases' 2025 Recommendations for the Initial Management of Suspected Paediatric Sepsis With or Without Shock.” Acta paediatrica (Oslo, Norway : 1992) (2025). PMID: 40719519 ↗
L1cGUIDELINECited in: Guidelines and Resources - [241]
Silverstein M, Wong JB, Davis EM et al.. “Screening for Syphilis Infection During Pregnancy: US Preventive Services Task Force Reaffirmation Recommendation Statement.” JAMA (2025). PMID: 40358930 ↗
L1cGUIDELINECited in: Guidelines and Resources - [242]
Chang CC, Harrison TS, Bicanic TA et al.. “Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM.” The Lancet. Infectious diseases (2024). PMID: 38346436 ↗
L1cGUIDELINECited in: Guidelines and Resources - [243]
Cook AM, Morgan Jones G, Hawryluk GWJ et al.. “Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients.” Neurocritical care (2020). PMID: 32227294 ↗
L1cGUIDELINECited in: Guidelines and Resources - [244]
Beier AD, Nikas DC, Assassi N et al.. “Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Closure of Myelomeningocele Within 48 Hours to Decrease Infection Risk.” Neurosurgery (2019). PMID: 31418041 ↗
L1cGUIDELINECited in: Guidelines and Resources - [245]
. “Committee Opinion No. 712: Intrapartum Management of Intraamniotic Infection.” Obstetrics and gynecology (2017). PMID: 28742677 ↗
L1cGUIDELINECited in: Guidelines and Resources - [246]
. “Committee Opinion No. 712 Summary: Intrapartum Management of Intraamniotic Infection.” Obstetrics and gynecology (2017). PMID: 28742671 ↗
L1cGUIDELINECited in: Guidelines and Resources - [247]
Vergnano S, Buttery J, Cailes B et al.. “Neonatal infections: Case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.” Vaccine (2016). PMID: 27491687 ↗
L1cGUIDELINECited in: Guidelines and Resources - [248]
McGill F, Heyderman RS, Michael BD et al.. “The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults.” The Journal of infection (2016). PMID: 26845731 ↗
L1cGUIDELINECited in: Guidelines and Resources - [249]
Bower WA, Hendricks K, Pillai S et al.. “Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident.” MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (2015). PMID: 26632963 ↗
L1cGUIDELINECited in: Guidelines and Resources - [250]
Mazzola CA, Choudhri AF, Auguste KI et al.. “Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: Management of posthemorrhagic hydrocephalus in premature infants.” Journal of neurosurgery. Pediatrics (2014). PMID: 25988778 ↗
L1cGUIDELINECited in: Guidelines and Resources - [251]
. “Committee Opinion No. 614: Management of pregnant women with presumptive exposure to Listeria monocytogenes.” Obstetrics and gynecology (2014). PMID: 25411758 ↗
L1cGUIDELINECited in: Guidelines and Resources - [252]
Solomon T, Michael BD, Smith PE et al.. “Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines.” The Journal of infection (2012). PMID: 22120595 ↗
L1cGUIDELINECited in: Guidelines and Resources - [253]
Kneen R, Michael BD, Menson E et al.. “Management of suspected viral encephalitis in children - Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group national guidelines.” The Journal of infection (2012). PMID: 22120594 ↗
L1cGUIDELINECited in: Guidelines and Resources - [254]
. “Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).” MMWR. Morbidity and mortality weekly report (2010). PMID: 20814406 ↗
L1cGUIDELINECited in: Guidelines and Resources - [255]
Bertsias GK, Ioannidis JP, Aringer M et al.. “EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.” Annals of the rheumatic diseases (2010). PMID: 20724309 ↗
L1cGUIDELINECited in: Guidelines and Resources - [256]
Wright JG, Quinn CP, Shadomy S et al.. “Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.” MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports (2010). PMID: 20651644 ↗
L1cGUIDELINECited in: Guidelines and Resources - [257]
Mygland A, Ljøstad U, Fingerle V et al.. “EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis.” European journal of neurology (2010). PMID: 19930447 ↗
L1cGUIDELINECited in: Guidelines and Resources - [258]
Thwaites G, Fisher M, Hemingway C et al.. “British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children.” The Journal of infection (2009). PMID: 19643501 ↗
L1cGUIDELINECited in: Guidelines and Resources - [259]
Chaudhuri A, Martinez-Martin P, Kennedy PG et al.. “EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.” European journal of neurology (2008). PMID: 18582342 ↗
L1cGUIDELINECited in: Guidelines and Resources - [260]
Halperin JJ, Shapiro ED, Logigian E et al.. “Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED].” Neurology (2007). PMID: 17522387 ↗
L1cGUIDELINECited in: Guidelines and Resources - [261]
. “Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.” Pediatrics (2006). PMID: 16382131 ↗
L1cGUIDELINECited in: Guidelines and Resources - [262]
Rauer S, Kastenbauer S, Dersch R et al.. “Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis.” German medical science : GMS e-journal (2025). PMID: 41195425 ↗
L1cGUIDELINECited in: Guidelines and Resources - [263]
Schwarz Chavarri G, Sánchez Hernández C, Moreno Millán N et al.. “[Infectious Disease Prevention Group. Update on vaccines, 2020].” Atencion primaria (2020). PMID: 33388119 ↗
L1cGUIDELINECited in: Guidelines and Resources - [264]
Rauer S, Kastenbauer S, Hofmann H et al.. “Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis.” German medical science : GMS e-journal (2020). PMID: 32341686 ↗
L1cGUIDELINECited in: Guidelines and Resources - [265]
Tanaka Y, Kuwana M, Fujii T et al.. “2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases.” Modern rheumatology (2021). PMID: 31903831 ↗
L1cGUIDELINECited in: Guidelines and Resources - [266]
Truffert E, Fournier Charrière E, Treluyer JM et al.. “Guidelines of the French Society of Otorhinolaryngology (SFORL): Nonsteroidal anti-inflammatory drugs (NSAIDs) and pediatric ENT infections. Short version.” European annals of otorhinolaryngology, head and neck diseases (2019). PMID: 31420238 ↗
L1cGUIDELINECited in: Guidelines and Resources - [267]
Risser A, Donovan D, Heintzman J et al.. “NSAID prescribing precautions.” American family physician (2009). PMID: 20000300 ↗
L1cGUIDELINECited in: Guidelines and Resources - [268]
Martins B, Canelas G, Dias R et al.. “[Diagnostic, Therapeutic and Monitoring Approach in Suspected Neurosyphilis: Proposal for a Clinical Guideline].” Acta medica portuguesa (2024). PMID: 39622197 ↗
L1cGUIDELINECited in: Guidelines and Resources